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1.1 Transporters and Drugs 
The cell membrane contains a plethora of transporter proteins embedded in the lipid bilayer. The 
interplay between these transporters controls the passage of different compounds from endo- and 
exogenous origin through the cell. The majority of transporters belong to two superfamilies, the ATP-
binding cassette (ABC) transporters and Solute Carriers (SLCs). Multispecific drug transporters with 
overlapping substrate specificity can be found in both families and they play a crucial role in the 
absorption, distribution, and elimination of their substrates. These proteins are localized to critical 
barrier surfaces such as liver, kidney, brain, lung, intestine, testes and placenta. While extensive 
research has been focused on ABC transporters due to their role in drug resistance and the 
pathogenesis of several diseases (e.g.: cystic fibrosis, pseudoxanthoma elasticum), recent studies are 
also focusing on the role of SLCs in drug-drug interactions (DDIs) and pharmacokinetics (PK). One 
such family, the Organic anion-transporting polypeptides (OATPs) stands out as a major contributor 
to these findings. The human OATP family has 11 members that are involved in the cellular uptake 
of various organic compounds, including widely prescribed drugs such as statins, antibiotics, 
antimycotics, anticancer agents, etc. Modulation of OATP function or expression via 
pharmacotherapy with OATP substrates/inhibitors or due to polymorphisms affects 
pharmacokinetics. Moreover, these alterations could manifest themselves into drug toxicities which 
has been a major concern in drug development. These toxicities can arise from multiple sources, e.g. 
a combination of drugs and genetically predisposed vulnerabilities (polymorphisms). According to 
current industry standards, in vitro testing for susceptibility to the transport by liver-specific OATP1B1 
and OATP1B3 is recommended for drug candidates that are eliminated in part via the liver. Also, 
OATP1B1 and OATP1B3 are essential in hepatic transport, but they are also known for their role in 
statin-related DDI risk and have clinically relevant polymorphisms. Although, there is a growing 
interest in utilizing OATPs for targeted drug delivery, given their broad substrate specificity and their 
cancer-specific expression, most members of the OATP family are poorly characterized. This is due 
to multiple factors that complicate the study of this family such as lack of specific substrates and 
inhibitors, non-standard in vitro tools and a limited number of cellular models with well-defined 
transporter expression.  
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Hence the objectives of this thesis are to: i) develop a robust assay platform to study the OATPs’ 
function and ii) to describe new OATP-drug interactions. Such knowledge may help us to enhance 
our understanding of transporter function, interpret observed pharmacological effects and make more 
accurate predictions of potential adverse and off-target effects. 
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1.2 The SLCO/OATP family 
Organic anion transporting polypeptides (OATPs) are members of the SLC superfamily. This 
superfamily has 65 families and more than 400 different human transporters accomplishing vital 
physiological functions from nutrient uptake through neurotransmitter transport to absorption of 
widely marketed drugs and xenobiotics. The human SLCO gene family (former SLC21) encoding 
OATPs have 11 members. OATPs are expressed in the membrane of various epithelial and endothelial 
cells and mediate the sodium and ATP-independent uptake of large organic ions and amphipathic 
compounds into cells. Although no crystal structure is available yet for any of the OATPs, topology 
predictions suggest 12 transmembrane helices with intracellular N- and C-termini 1. OATPs are 
divided into six subfamilies based on >40% amino acid sequence identity and identified by Arabic 
numbering (OATP1-OATP6) 2. Four members of the family have been characterized in detail. These 
are OATP1A2, OATP1B1, OATP1B3 and OATP2B1 and owing to their role in altering 
pharmacokinetic parameters of drugs, multispecific substrate profile and cancer-specific expression 
pattern makes them potential therapeutic targets 3. Regardless of the growing interest, the biochemical 
and pharmacological characterization of the family is far from being complete and several members 
lack the experimental framework required to investigate their transport mechanism and substrate 
specificity. This chapter aims to give an overview of OATPs in general, their involvement in drug-
transporter interactions and in vitro methods designed to investigate OATP-drug interactions. 
1.2.1 Tissue distribution and localization of OATPs in healthy tissues 
OATPs are localized to the plasma membrane of epithelial and endothelial cells and are widely 
expressed through the human body. The available expression profiles for OATPs are characterized 
mainly by RT-PCR, which only indicates mRNA levels. However, there are publications that relied on 
specific antibodies narrowing down their cellular localizations. We have previously published a review 
where we summarized available data for each OATP in regard of expression patterns and subcellular 
localization in healthy tissues 4. Table 1.1 and Figure 1.1 contain an updated version of these data 
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ubiquitous: blood-brain barrier 
(BBB) 5,6, eye (retina)7,8, intestine 9, 
kidney (distal tubule) 5, liver 
(cholangiocytes)5, neurons 7, 
placenta 10, red blood cells 11 
mainly apical 670 12p12 
SLCO1B1 OATP1B1 liver (hepatocytes) 12 basolateral 
(sinusoidal) 
691 12p12 
SLCO1B3 OATP1B3 liver (hepatocytes) 
13, pancreas 




SLCO1C1 OATP1C1 brain (choroid plexus), testis 
(Leydig cells) 15,16 
basolateral 712 12p12 
SLCO2A1 OATP2A1 
ubiquitous: eye (retina, ciliary 
epithelium) 17, endometrium 18, 
neurons 19, intestine 20 
n.d. 643 3q21 
SLCO2B1 OATP2B1 
ubiquitous: BBB 6, liver 
(hepatocytes) 21, intestine 1,20, 
skeletal muscle 22, red blood cells 







brain (choroid plexus, neurons) 




in the brain) 
710 15q26 
SLCO4A1 OATP4A1 
ubiquitous: eye (ciliary body) 24, 
kidney 25, pancreas 25, heart 25, 
placenta 26, intestine20 
apical 722 20q13.1 
SLCO4C1 OATP4C1 kidney 27 
 
basolateral 724 5q21 
SLCO5A1 OATP5A1 breast 
28, heart 29, fetal brain 29, 
skeletal muscle 29 
n.d. 848 8q13.1 
SLCO6A1 OATP6A1 brain 30, testes 31 n.d. 719 5q21 
Table 1.1 Gene names and their protein products, tissue distribution, amino acid numbers and 
chromosome localizations of the human OATPs. Tissues and organs highlighted with bold letters represent 
protein expression data. n.d.: Localization data is not available. 
Pharmacologically important members are primarily expressed in tissues important in drug 
disposition, such as OATP1B1, OATP1B3, OATP2B1 in the liver (OATP2B1 is also highly expressed 
in the intestine), OATP4C1 in the kidney, and OATP1A2 (and OATP2B1) in the blood-brain barrier 
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(BBB). Other members are either expressed ubiquitously through the body or have more restricted 
tissue distribution patterns.  
 
Figure 1.1 Expression of OATPs in selected human epithelial and endothelial cells. Question marks 
indicate that the expression has been demonstrated but the localization has yet to be shown. OATP3A1 has 
two isoforms (V1 and V2) with distinct localization. Figure was created with Biorender.com 
1.2.2 Structure of human OATPs 
Human OATPs share more than 30% amino acid identity and their size range between 634 and 848 
amino acids (see Table 1.1). Based on hydrophobicity analyses, OATPs are proposed to have a 12 
transmembrane segment (TM) topology with both N- and C-termini at the cytoplasmic side of the 
cell membrane. There are distinct characteristics that help separate OATPs from the rest of the SLC 
superfamily. For instance, all OATPs share a highly conserved OATP-signature sequence: D-X-RW-
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(I, V)-GAWW-X-G-(F, L)-L. In OATP1B1 it is located in the boundary of the 3rd extracellular loop 
and the 6th TM domain 32 (Figure 1.2.) and it is important for the surface expression of this protein 
33. The second typical feature is the large extracellular domain (5th extracellular loop) with 
conserved cysteines which is required for the surface expression of OATP2B1 34,35. Additionally, in 
the same loop, previous studies identified a distant homology to the Kazal-type serine protease 
inhibitors. Although this domain is usually associated with protein kinase inhibitors, there is no 
existing research showing any relevance for OATPs’ function. 
 
Figure 1.2 Predicted transmembrane structure of OATP1B1. This prediction was created with the help of 
the HMMTOP server 36. 
OATP family members also have a PDZ consensus sequence on the C termini. the motif 
X(S/T)XΦ, where X is any amino acid, and Φ is a hydrophobic amino acid. Wang et al. studied the 
function of the PDZ domain in Oatp1a2 (rat) and have found that oligomerization with the PDZK1 
protein is essential for proper subcellular localization and function of Oatp1a2. In PDZK1 knock-out 
mice, it was localized to intracellular membranes, resulting in an impaired clearance of 
bromosulfophtalein 37. Kato et al. provided further proof, demonstrating that interaction with PDZ 
proteins are essential for the plasma membrane localization for human OATP1A2, OATP3A1 and 
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OATP1C1 38. OATPs also contain several N-glycosylation sites in their 3rd and 5th extracellular loops. 
In the case of OATP1B1 N-glycosylation has been shown to dictate proper localization and stability 
of the protein 39. Another conserved element in OATPs is the His, found in the 3rd transmembrane 
segment. This His has been proposed as a pH sensor 40 (read more in 1.2.3). Nevertheless, as there is 
no OATP crystal structure available, one can only rely on homology models and site-directed 
mutagenesis studies to predict the structure-function relationships of OATPs 41. 
1.2.3 Transport mechanism 
The mechanism of OATP-mediated transport is not completely understood. It is generally accepted 
that the transport is electroneutral, independent of sodium gradient and is not directly coupled to ATP 
hydrolysis 35. However, it is unclear whether this involves the coupled movement of another 
compound or counter ion across the membrane, or if it follows facilitated diffusion through the central 
pore of the OATP. The proposed transport mechanism for this family is the so-called rocker-switch 
type mechanism based on the analyses of amino acid conservation patterns, transport activity, 
substrate specificity and homology modeling 41. Nevertheless, studies with rat Oatp suggest that they 
act as bicarbonate, glutathione or glutathione conjugate exchangers 23,35. Also, transport can be 
enhanced with an acidic extracellular milieu 2,40,42. There are theories trying to explain why OATPs 
have a broader substrate specificity and enhanced transporter activity at acidic pH. For example, 
Varma et al. suggest it might be the result of a change in the degree of protonation of the substrate or 
the substrate-binding pocket of the transporter. He also used a proton ionophore FCCP (carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone) and successfully inhibited OATP2B1-mediated uptake 
of estrone-3-sulphate and several statins at acidic extracellular pH 43. Leuthold et al. mutated the highly 
conserved histidine in the 3rd transmembrane domain, the predicted pH sensor, and argued that the 
protonation of this conserved His at acidic extracellular pH might responsible for increased affinity 
toward anionic substrates 40. There is additional evidence suggesting that the transport might be driven 
by proton gradient 42. Additionally, inhibition studies have also shown that different compounds can 
have different effects on OATP-mediated transport. For example, clotrimazole was shown to 
stimulate OATP1B3-driven estradiol-17β-glucuronide uptake in stable transfected CHO cells. 
However, in the same paper they also showed that clotrimazole inhibited OATP1B1-mediated 
estradiol-17β-glucuronide uptake 44. It appears that there are significant functional differences within 
the OATP family, and the function could be influenced in a substrate- and pH-dependent manner. 
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1.2.4 Substrate specificity 
Substrates of OATPs are mainly large amphipathic organic compounds (˃300 Da), including steroid 
hormones, and their conjugates, bile salts, toxins and drugs 30. Due to their physiological function 
OATPs are important contributors to bile acid homeostasis (OATPs, 1A2, 1B, 1C1, 2B1, 4A1 and 
4C1), bilirubin elimination (OATPs, 1A2, 1B1 and 1B3), inflammatory processes and hormone level 
adjustments 35,45 (See Table 1.2 for physiological OATP substrates). On top of that, they are known 
to recognize wildly prescribed medications such as statins, anticancer agents, and antibiotics 45. OATPs 
exhibit a broad and overlapping substrate specificity with other members of the SLC and ABC-
transporter families. For instance, OATPs and ABCs work together in the hepatic clearance 46, and 
toxicity could occur if this essential function is altered by SNPs (single nucleotide polymorphisms), 
drug-drug or drug-food interactions 47–49. For instance, co-administration of statins (cholesterol-
lowering drugs) with another OATP-inhibitor, cyclosporine A led to toxicity and statin-induced 
myopathy 22,50. This helped to recognize the importance of OATPs in drug-transporter interactions. 
This aspect will be discussed further in the Clinical significance section of this dissertation.  
OATP Physiological substrates 
1A2 
• atROL 8 • bile salts (taurocholate, cholate, ursodeoxycholic acid) 35,51 •bilirubin 35 • 
hormones (T4, DHEAS, E1S)35 • PGE2 35 • neuropeptides: SP, VIP 7 
1B1 
• bile salts (taurocholate, tauroursodeoxycholate) 35 • bilirubin 35 • eicosanoids (LTC4, 
LTE4, PGE2, thromboxane B2) 32 • hormones (E1S, E17βG, T3, T4, DHEAS 35 
1B3 
• bile salts (cholate, glycocholate, taurocholate, taurochenodeoxycholate, 
taurodeoxycholate, tauroursodeoxycholate) 35 • bilirubin 35 • CCK-8 52 • hormones (T3, 
T4, E1S, DHEAS, testosterone) 35 • LTC4 35 • steroid conjugates 30 
1C1 • hormones (E1S, E17βG, thyroid hormones) 30,35 
2A1 • PGs (PGE1, PGE2, PGD2 ,PGF2α) 53 
2B1 
• DHEAS 54 • E1S 35 • LTC4 54 • neuropeptides: SP, VIP 7 • PGE2 35 • taurocholate 42,54 • 
thromboxane B2 53 
3A1 • E1S 15 • PGE1, PGE2 15 • T4 54 • vasopressin 15 
4A1 • E17βG 35 • E1S 35 • PGE2 12 • thyroid hormones (T4, rT3(weak), T3, taurocholate 25) 
4C1 • cAMP 27 • E1S 55 • thyroid hormones 27 
5A1 no data 
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6A1 no data 
Table 1.2 Physiological OATP substrates. This table was based on Kovacsics et al., 2016 4 Abbreviations: 
atROL: all-trans-retinol, CCK-8: cholecystokinin, DHEAS-dehydroepiandrosterone sulfate, E1S: estrone-3-
sulphate, E17βG: estradiol-17β-glucuronide, LTC4: leukotriene C4, LTE4: leukotriene E4, PGE: 
prostaglandin E, PGD: prostaglandin D, PGF: prostaglandin F, SP: guinea pig anti-substance P, T3: 3,3’,5-
triiodothyronine, T4: thyroxine VIP: sheep anti-vasoactive intestinal peptide 
1.2.5 Clinical significance 
1.2.5.1 OATPs associated with diseases 
Several SNPs and mutations in the SLCO genes have been linked to diseases. For example, OATP1B1 
and OATP1B3 are expressed on the sinusoidal membrane of hepatocytes. They facilitate the uptake 
of their substrates, such as bilirubin, bile acids, hormones, and drugs. Simultaneous null mutations in 
SLCO1B1 and SLCO1B3 lead to Rotor-type hyperbilirubinemia, an autosomal recessive disorder 
characterized by jaundice and elevated serum levels of bilirubin glucuronide 56. If hepatocytes lack 
functional OATP1B1 and OATP1B3, there is a failure in the reuptake of conjugated bilirubin from 
the blood into the liver 56. Even though OATP1B1 and OATP1B3 have significant roles in drug 
detoxification, such functional discrepancies are still compatible with relatively normal life and Rotor 
syndrome is a mild phenotype. 
Genome-wide association studies (GWAS) help to identify genetic traits, regions and SNPs that could 
be associated with certain diseases. Using this approach, a SNP in SLCO1A2 (rs11568563) resulting 
in a Glu172Asp change (causing defective membrane trafficking and decreased function) was found 
to be involved in progressive supranuclear palsy (PSP). PSP is a Parkinsonian neurodegenerative 
disorder that presents with predominant specific four repeats (4R) tauopathy in basal ganglia, 
brainstem and diencephalon with neuronal loss and fibrillary gliosis 57. Other associations were 
described between SLCO6A1 and schizophrenia (rs6878284, an intron variant), bipolar disorder 
and MDD (major depressive disorder) (rs7734060, intron variant) 58,59.  rs6878284 is significant in 
the Swedish population; however analysis of Han Chinese population didn’t reciprocate the previous 
finding but found rs7734060 in strong association with MDD 58. The primary reason for this 
discrepancy in schizophrenia could be explained by genetic heterogenicity amongst the Asian and 
Caucasian populations. In addition, another variant of SLCO6A1 (rs7705924, intron variant) was 
associated with Crohn`s disease in Ashkenazi Jewish cohorts 60. 
The first report of deficient OATP1C1 was identified in a 15-year-old patient with severe brain 
hypometabolism and juvenile neurodegeneration. Exome sequencing revealed the disease causing 
homozygous missense mutation in the SLCO1C1 gene resulting in an Asp252Asn change. The 
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mutant protein showed impaired plasma membrane localization and decreased T4 uptake activity 61 
Treatment with a T3 analog (Triac) resulted in improved clinical condition and improved quality of 
life. The group hypothesized that the impaired OATP1C1 function likely reduced T4 uptake in 
astrocytes and its consequent conversion to T3. Therefore, it has led to reduced bioavailability of T3 
in target cells within the central nervous system which might explain the observed developmental 
delay, abnormal energy metabolism and subsequent neurodegeneration 61. More on OATP-related 
diseases check Kovacsics et al., 2016 4. 
1.2.5.2 Ectopic expression of human OATPs 
Some OATPs are highly expressed in tumors with low or undetectable expression in corresponding 
healthy tissues which makes them potential therapeutic targets 62–64. Increased or ectopic expression 
of OATPs has been found in breast, liver, colon, lung, pancreatic and ovarian cancers suggesting 
potential roles for OATPs in tumor development. As most of these OATPs transport 
chemotherapeutic substrates, their function may sensitize these tissues to cytotoxic agents. Hence 
targeting these transporters could increase therapy response and might improve overall survival rates. 
Moreover, given their ability to transport hormones, OATPs might affect cancer development by 
increasing the proliferation of hormone-sensitive tumors. Therefore, OATPs have been studied to 
evaluate their potential as diagnostic markers or possible therapeutic targets 65. Here are a few examples 
to illustrate how OATPs might affect cancer progression: First, estrone-3-sulfate uptake by OATPs, 
1A2 66, 1B3 67, 3A1, and 4A1 has been associated to the survival of hormone-dependent breast cancer 
cells 68. Second, OATPs also influence disease development in androgen-dependent prostate cancers. 
The Gly334Thr (rs4149117) allelic variant of OATP1B3 was shown to mediate the increased uptake 
of testosterone and is associated with decreased patient survival 69. In another prostate cancer study, 
they identified a testosterone transport-deficient variant of OATP1B3 (haplotype 334GG/699AA) 
which was associated with increased survival over 10 years 70. Similarly, an OATP2B1 variant 
Arg312Gln (rs12422149), with increased DHEAS (dehydroepiandrosterone sulfate) transport, was 
correlated with increased patient mortality 69. At last, as we mentioned above ectopic expression of 
OATP1B3, identified in cancerous tissues either by immunohistochemistry or based on RT-PCR 
results, can be found in several types of cancer (colon, breast, prostate, pancreatic, bladder and 
endometrial) 71. For several years it has been a generally accepted view that the canonical OATP1B3 
(702 amino acid) was identified in cancerous tissues. However, in 2012 and 2013, two cancer-specific 
isoform (OATP1B3 CT 72 and OATP1B3 V1 73) were discovered by two independent groups. The 
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OATP1B3 CT described by Nagai et al., was found in colon and lung cancer, OATP1B3 V1 was 
detected in pancreatic and colon cancer tissues. As these proteins are lacking either 47 (OATP1B3 
CT) or 28 (OATP1B3 V1) amino acids from the N-terminal end of the canonical OATP1B3 protein, 
there is an ongoing debate whether these isoforms exhibit plasma membrane localization and 
transporter function 72–74. Regardless, they carry a potential to become a diagnostic and prognostic 
markers for colorectal cancer 75–77. In Chapter III we will take a brief look on their expression, 
localization and function in different cell lines.  
In summary, as a consequence of many contradictory reports, it is hasty to propose whether the 
presence or absence of a certain OATP in a given cancer is predictive of patient survival or the success 
of hormonal or antineoplastic therapy. There are comprehensive reviews summarizing OATPs’ 
involvement in cancer: Kovacsics et al., 2016 4 and Schulte et al., 2019 64.  
1.2.5.3 Drug-transporter interactions 
One of the main reasons why OATPs gained recognition was their involvement in drug disposition. 
It is critical to predict drug-drug, drug-food and drug-transporter interactions and the in vivo fate of 
future/already marketed drugs. Multispecific OATPs, 1A2, 1B1, 1B3 and 2B1 have documented 
influence on the uptake, disposition and other pharmacokinetic parameters of their substrates. 
Alterations in their genes may, therefore, account for the interindividual differences in efficacy and 
toxicity of drugs. Moreover, transporter polymorphisms may not only affect systemic exposure but 
also local exposure, which is a greater challenge to screen. The family has a plethora of published 
research on OATP-mediated drug-drug interactions. Excellent reviews summarize the most important 
ones: Alam et al., 2019 and Shitara et al., 2017 in context of hepatic clearance (OATP1B1 and 
OATP1B3) 78,79, Ivanyuk et al., 2017 for renal DDIs (OATP1A2 and OATP4C1) 80, and Tamai et al., 
2013 for OATP2B1 mediated drug absorption and the potential influence of different fruit juices on 
OATP2B1 function and expression 81. Additionally, The U.S. Food and Drug Administration (FDA) 
published its own list of OATP FDA-approved drug interactions 82. Consequently, the International 
Transporter Consortium (ITS) recognizes OATPs, 1A2, 1B1, 1B3, and 2B1 as major determinants of 
PK and recommends the investigation of these transporters during drug development 83. The 
European Medicines Agency (EMA) also agrees with the necessity to describe specific polymorphisms 
in drug transporters and their possible effect on the efficacy and safety of medicinal products 84. 
Collectively, the biggest challenge remains to extrapolate in vitro data to relevant in vivo predictions. In 
Table 1.3 see a summary of the most relevant in vitro and in vivo OATP-drug interactions. 
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OATP Substrates and inhibitors in vitro Drug interactions in vivo  
1A2 
Antibiotics 
•direct TBPM-PI (β -lactam antibiotic) uptake 85 
Anesthetics and analgesics 
•direct deltorphin II and DPDPE transport 86 
•direct rocuronium transport inhibited by APM, 
taurocholate, K-strophantoside, QD, and NMQD 87 
Anticancer drugs 
•ES uptake inhibited by MTX 88 
• imatinib transport inhibited by naringin 89 
Antihypertensive drugs 
•direct nadolol uptake inhibited by green tea, naringin, 
verapamil 90 
•direct talinolol uptake 91 
Antihistaminic drugs 
•direct fexofenadine uptake 92 
•direct fexofenadine uptake  inhibited by naringin and 
hesperidin 93 
Antiretroviral drugs 
•direct SQV uptake 94 
Statins 
•direct pravastatin uptake 95 
Toxins 
•direct microcystin transport 96 
Others 
•direct ES uptake inhibited by atROL, direct atROL 
transport 8 
•direct TCL uptake 97 
•direct uptake measurements with triptans 98 
 
For further list of interacting molecules see 35,99,100 
•reduced fexofenadine AUC by 
citrus juices 92,101  
•imatinib pharmacokinetics 
affected by SLCO1A2 SNPs in 
CML patients 89 
•green tea ingestion decreases 
plasma concentrations of nadolol 
in humans, presumably in part by 
inhibition of OATP1A2-mediated 
intestinal absorption of nadolol 90 
•docetaxel transport in humanized 
mice 102  
1B1 
Antibiotics 
•ES uptake inhibited by several anti-TB drugs 103 
•E17βG uptake inhibited by novobiocin 104 
Anticancer  
•direct docetaxel uptake 105 
•direct flavopiridol uptake and increased toxicity 106 
•involved in toxicity and disposition of platinum anticancer 
drugs 107 
•TKIs as 1B substrates (e.g. direct sorafenib transport) 108 
Antihypertensive drugs 
•direct bosentan uptake inhibited by CsA and rifampicin 109 
•direct valsartan uptake 110 
Anti-inflammatory drugs 
•direct mesalazine transport inhibited by budesonide, 
cyclosporine A, rifampin 111 
Statins 
•transport inhibitors: lovastatin acid, pravastatin acid, and 
simvastatin acid 104 
•direct cerivastatin uptake inhibited by CsA 112 
•rifampicin as an inhibitor of 
OATP1B1 and OATP1B3 
•Oral or intravenous dose of 
rifampicin increases exposure of 
rosuvastatin and pitavastatin 116 
•docetaxel transport (humanized 
mice) 102  
•role for OATP1Bs in the 
elimination of sorafenib 
(humanized mice) 108 
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•cerivastatin mediated toxicity caused by 1B1 inhibition 
with gemfibrozil 113 
Toxins 
•direct microcystin transport and cytotoxicity 96,114 
 
For further interacting molecules see 35,54,99,100,104,115 
1B3 
Antibiotics 
•ES uptake inhibited by several anti-TB drugs 103  
•direct E17βG uptake inhibited by novobiocin 104 
Anticancer drugs 
•direct paclitaxel transport 117 
•transport inhibitors: mitoxantrone and vincristine 27 104 
•direct docetaxel transport 105 
•direct flavopiridol uptake and increased toxicity 106 
•1B3 linked toxicity and disposition of cisplatin, 
carboplatin, and oxaliplatin 107 
•TKIs as 1B substrates (e.g. direct sorafenib transport)108 
Anti-inflammatory drugs 
•direct mesalazine transport inhibited by budesonide, 
cyclosporine, rifampin 111 
Antihypertensive drugs 
•direct bosentan uptake inhibited by CsA and rifampicin 109 
•direct valsartan uptake 110 
Toxins 
•direct microcystin transport and cytotoxicity 96,114 
 
For an exhaustive list of interacting molecules see: 
35,54,99,100,104 
•imatinib pharmacokinetics 
affected by SNPs in CML 
patients 118 
•paclitaxel pharmacokinetics 
affected by SNPs 117 
•docetaxel transport (humanized 
mice) 102 
•role for OATP1Bs in the 
elimination of sorafenib 
(humanized mice) 108  
•rifampicin as an inhibitor of 
OATP1B1 and OATP1B3 116 
•rifampicin as an inhibitor of 
OATP1B1 and OATP1B3 
•Oral or intravenous dose of 
rifampicin increases exposure of 
rosuvastatin and pitavastatin 116  
1C1 •direct docetaxel transport 105   
2A1 
Anti-inflammatory drugs 
•direct PGE2 uptake inhibited by diclofenac and 
lumiracoxib 119 
•direct PGE2 uptake induced by indomethacin, ketoprofen, 
and naproxen 119 
Flavonoids 
•direct quercetin transport 120 
Prostaglandin analogs 




•direct ES uptake inhibited by several anti-TB drugs 103 
•direct TBPM-PI (β -lactam antibiotic) uptake 85 
•direct ES uptake inhibited by novobiocin 104 
Anticancer drugs 
•transport inhibitor: erlotinib 104 
•direct flavopiridol uptake and increased toxicity 106 
Anti-inflammatory drugs 
•direct mesalazine transport inhibited by budesonide, 
cyclosporine, rifampin 111 
•direct DCF-AG transport and toxicity 121 
Antihypertensive drugs 
•direct talinolol uptake 91  
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Prostaglandin analogs 
•direct latanoprost acid uptake 17 
Statins 
•transported by 2B1 99 
•involved in increased cytotoxicity of statins 22 
 
For further interacting molecules see: 35,54,99,100,104 
3A1 
Antibiotics 
•direct benzylpenicillin transport 12 
Antihypertensive drugs 
•direct BQ-123 transport 23 
•3A1 as a novel CD-associated 
gene, results higher incidence of 








•direct sitagliptin transport 123 
Cardiac glycosides 
•direct digoxin transport 27,123 
•direct digoxin transport increased by bupropion 124 
Statins 




cardiomegaly, and inflammation 
in a rat renal failure model 125 
5A1 
Anticancer drugs 
•5A1 expressing cells showed higher resistance to 
satraplatin 126 
Flavonoids 
•direct quercetin uptake 120 
 
6A1     
Table 1.3 OATP transporter activity and drug-disposition assessed in vivo (human clinical or rodent 
data). This table was part of my contribution to the review we published earlier (Kovacsics et al.,2016)4 
Abbreviations: atROL: all-trans-retinol; CsA: cyclosporin A; CD: Crohn’s disease; CML: chronic myeloid 
leukemia; DCF-AG: diclofenac acyl glucuronide; DPDPE: [D-penicillamine2,5]encephalin; ES: estrone-3-
sulphate; E17βG: estradiol-17β-glucuronide; MTX: methotrexate; PGE: prostaglandin E; TBPM-PI: 
tebipenem pivoxil; TCL: trospium chloride; TKI: tyrosine kinase inhibitors; SQV: saquinavir mesylate 
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1.3 Methods and models to investigate OATP-drug 
interactions 
1.3.1 Test substrates 
Most regulatory agencies require preclinical ADME (absorption, distribution, metabolism and 
elimination) studies prior to human trials to make better estimates about tissue exposures of potential 
new drugs and their metabolites. These studies are crucial to select optimal doses and toxicological 
test systems for future safety evaluation 127. As yet, the most efficient way to advance our 
understanding of ADME properties of a drug is to use radioactive isotopes to label and then track a 
new chemical entity either in in vivo or in in vitro model systems. So far, radioactively labeled drugs were 
the best choice to localize and quantify the route of a compound through organs, tissues, and cells. 
Of course, radiolabeled studies have their limitations, among which is the fact that the measured data 
reflects both the original compound and its metabolites. Furthermore, it is also costly to tag a 
compound with [14C] (radiocarbon) or [3H] (tritium), which makes them less favorable for larger-scale 
substrate-screening experiments 127. Therefore, efforts have been made to establish newer techniques 
using mass spectrometry (MS) and compounds with fluorescent tags. Still the use of radioactively 
labeled compounds in in vitro models for screening and estimating drug-transporter interactions has 
become the standard way to study OATP function. Radiolabeled estrone-3-sulfate, bromsulphthalein, 
and estradiol 17 β-D- glucuronide have been used for many years to determine the transport activity 
of several OATPs 42,128–130. On the other hand, mass spectrometry can also be used to get quantitative 
ADME or transport data, although it requires more resources, and more efforts to get appropriate 
standards and to determine individual tissue concentrations. However, mass spectrometry can be 
applied to follow the metabolism of a drug candidate. Finally, the growing need for imaging-based 
assays brought attention to fluorescent compounds and they proved to be excellent tools for in vivo 
imaging in drug discovery. The second most popular application of fluorescent compounds is using 
them in transport inhibition assays. A variety of fluorescent probes (Na-fluorescein 131, fluorescein-
methotrexate 132, fluorescein-cAMP 133, various fluorescent bile acids 134,135) have been used in indirect 
transport assays to identify OATP1B interacting compounds; however, until recently, no fluorescent 
assay has been available for other OATPs. Our laboratory was the first to show that sodium-
fluorescein (Na-Fluo) is a pan-human OATP substrate and it can also be used to describe poorly 
characterized OATP family members 136 (See Chapter I for details). The value of fluorescein 
derivatives to develop substrate inhibition assays for OATP1B and OATP2B1 transporters was also 
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shown in mammalian cells 133. However, concerns were raised as fluorescein proved to be cell-
permeant and its fluorescence intensity is pH-dependent (lowering the pH reduces the fluorescence 
intensity) 137. Also, the phenomenon of internal quenching occurs with fluorescein solutions. This 
means that above a certain concentration in aqueous solutions, the apparent fluorescence of 
fluorescein will decrease 138. Therefore, we wanted to identify a pH-independent fluorophore with 
minimal cell permeability, to perform transport measurements at acidic pH levels desired for the 
optimal activity of OATPs (Chapter II). Standard and newly developed test substrates of OATPs are 
listed in Table 1.4 (also including our findings).  
In summary, OATP-drug interaction assays with fluorescent probes are quick, cost-efficient, and suit 
big compound library screens. However, since the indirect assays do not necessarily distinguish 
between competitive and non-competitive inhibition, direct transport measurements verified by MS 
or radioactive labeling should be performed for the compounds identified by such screens.  
OATP 
(human) 
Fluorescent or radioactive substrates 
1A2 
• [3H] atROL 8, • [3H] BSP 90, • [35S] BSP 51, • [tyrosyl-3,5-3H] deltorphin II 86, • [3H] digoxin 
139, • [3H] docetaxel 102, • [tyrosyl-2,6-3H(N)] DPDPE 86, • [3H] ES 139, • Fl-MTX 136, • [3H] 
MTX 88, • [3H] nadolol 90, • LDG140, • LDV140, • LorD488140, • Na-Fluo 136, • [3H] PGE2 
139, • [3H] quercetin 120, • [3H] quinidine 87, • Rhodamine 123 141, • [3H] N- methyl-quinine 139, 
• SRB140, • SRG140, • SR101140, • [14C] SQV 94, • [3H] TCL 97, • ZV 140 
1B1 
• AF405142, 142• [3H] BSP 143, • [3H] BPS 144, • CB142, • DCF and DBF 133, • [3H] docetaxel 
105, • [3H] E17βG 145, • [3H] ES 143, • Fl-MTX 132, • Fluo-3 44, • Flutax-2 (Oregon Green 488-
Paclitaxel) 35, • LDG142, • LDV142, • Na-Fluo 131, • Oregon green 133, • [3H] TC 145, ZV142 
1B3 
• AF405142, • [3H] BSP 13, • [3H] BPS 144, • CB142, • [3H] CCK-8 52, • DBF 133, • [3H] 
docetaxel 105, • [3H] E17βG 13, • [3H] ES 139, • Fl-MTX 132, • Fluo-3 133, • Na-Fluo 131, • 
LDG142, • LDV142, • Oregon green 133, • [3H] TC 145, • [125I]-T3 139, • [125I]-T4 139, • ZV142 
1C1 
• [3H] BSP 16, • [3H] docetaxel 105, • [3H] E17βG 16, • [3H] ES 16, • LDG 140, • LDV 140, • 
LorD488 140, • Na-Fluo 136, • SR101 140,146, • SRB 140, • SRG140 
2A1 • Na-Fluo 136, • [3H] PGE2 53, • [3H] PGE1 53, • [3H] quercetin 120 
2B1 
• AF405 142, • [3H] BSP 139, • CB 142, • DCF and DBF 133, • [3H]-ES 12, • Fl-MTX 136, • LDG 
142, • LDV 142, • Na-Fluo 136, • Oregon green 133, • [3H] quercetin 120, • [3H] PGE2 12, • 
SR101140, • [3H]TC 42, • ZV142 
3A1 
• [prolyl-3,4(N)-3H]-BQ-123 23, • [3H]-ES 12, • Na-Fluo 136, • [3H] PGE2 23, • [3H] PGE1 23, 
• [tyrosyl-3,5(N)-3H]-vasopressin 23 
4A1 •[3H] ES 12, •[3H] PGE2 12, • Na-Fluo 136, •[3H] TC 25, •[125I] T4 25 
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4C1 • [3H] digoxin 27, • [3H] ES 40,55, • Na-Fluo 136, • [14C] and [3H] sitagliptin 123 
5A1 • Na-Fluo 136, • [3H] quercetin 120 
6A1 • Na-Fluo 136 
Table 1.4 Fluorescent and radiolabeled substrates used to study OATP function. An updated version of 
a table previously published by our group (Kovacsics et al.,2016)4 Abbreviations:  AF405: Alexa Fluor 405 
NHS Ester; BPS: Beraprost Sodium; BSP: Bromsulphthalein/ sulfobromophthalein; CB: Cascade Blue 
hydrazide; CCK-8: cholecystokinin; DBF: 4′,5′-dibromofluorescein; DCF: 2′,7′- dichlorofluorescein; DHEAS-
dehydroepiandrosterone sulfate; DPDPE: [D-penicillamine2;5]encephalin; ES: estrone-3-sulphate; E17βG: 
estradiol-17β-glucuronide; Fl-MTX: fluorescein-methotrexate; LDG: Live/Dead Green; LDV: Live/Dead 
Violet; LorD488: Live-or-Dye 488; Na-Fluo: sodium-fluorescein; PGE: prostaglandin E; SR101: 
sulforhodamine 101; SRB: sulforhodamine B; SRG: sulforhodamine G; SQV: saquinavir mesylate; TC: 
taurocholate; TCL: trospium chloride; T3: 3,3’,5-triiodothyronine; T4: thyroxine. Highlighted with bold letters 
represent the substrates that were described by our laboratory. 
1.3.2 In vitro models 
Nowadays a plethora of cellular models are available for the investigation of OATPs. The first 
established and still popular cell-based model to study OATP transport activity is based on cRNA-
injected Xenopus laevis oocytes. Although this model could offer only transient OATP-expression, 
it has been used for many years to characterize OATPs’ function and substrate-specificity 117,147–150. Sf9 
(Spodoptera frugiperda) insect cells have also been used for the investigation of OATPs 23,135,136,151. 
Although several mammalian cell lines (Caco-2 152,153, CHO 154, HeLa 155, HEK-293 108,154,156,157, 
HepG2 74,158, Huh7 158 etc.) were created to stably overexpress OATPs, there is evidence that 
generation of these cell lines is challenging 159. We also experienced difficulties generating stable OATP 
expressing cell lines (see more in Chapter II). One possible explanation to this phenomenon is the 
uptake of toxic compounds from cell culture media by overexpressed OATPs causing metabolic 
distress. There is another concern with loss or gain of function studies, as other endogenous 
transporters with overlapping substrate specificities can compensate for the metabolic changes which 
could baffle the results obtained with these studies 159.  
During the in vivo route of a drug through the human body the compound interacts with various 
transporters and may be modified by metabolic enzymes. To recapitulate the in vivo tissue environment 
and better understand this network, more complex methods are required. Keeping the 
pharmacological goal in mind, there were multiple options from which to choose. The simplest are 
cell lines expressing or co-expressing influx and efflux transporters and biotransformation enzymes 
160. More complex stem-cell-derived organoid cultures 161,162, precision-cut intestinal slices 163,164, 3D 
cell cultures 163 and bioreactors 165 are used to try to recapitulate the tissue heterogeneity.  
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Also, we should be mindful of the interpretation of the data we acquire with the cell-based in vitro 
systems. There are known prediction methods and guidelines that help to predict whether a new drug 
has the potential to inhibit OATP1B1 function. Vaidyanathan et al., 2016 compared the reliability of 
these prediction methods based on in vitro data. They concluded that they can reasonably predict a 
potential risk of OATP1B1-mediated clinical DDI, although we should better understand the 
variability in inhibition potency, and standardization of these prediction methods is the key 166. 
1.3.3 In vivo models 
As mentioned above, it is important to predict potential DDIs during the preclinical phase of drug 
development. It is a difficult task to extrapolate in vitro data to more complex in vivo processes. 
Therefore, animal models that may offer a better picture of drug disposition in the human is always 
of interest. Hepatic OATPs have been studied in mice, rats and primates at the systemic level. There 
are Oatp1a/1b knockout 167 and a Oatp1b2 (homolog of OATP1B1/1B3) knockout mice strains that 
have been used to study the liver and plasma distribution of toxins (phalloidin, microcystin- LR), 
cholesterol-lowering drugs (cerivastatin, lovastatin acid, pravastatin, and simvastatin acid), and 
antibiotics (rifampicin and rifamycin SV) 128,168. Alas, for some OATP members, no orthologs have 
been found in preclinical animal models such as rodents, and dogs 49. Hence better model is 
“humanized mice”. These are knockouts for the rodent Oatp, but have organ-specific expression of 
OATP1B1, OATP1B3 108,169. Such, OATP1A and OATP1B knockout and transgenic mice 
demonstrated the importance of OATPs in the plasma and hepatic clearance of anticancer drugs such 
as taxanes, irinotecan/SN-38, methotrexate, doxorubicin, and platinum compounds 170. However, it is 
important to point out that OATP1A2 is also expressed in the hepatocytes of the “humanized” mouse 
model, while OATP1A2 expression is limited to cholangiocytes in humans  168. Currently, there is no 
rodent model for OATP2B1. To help to better understand the role of OATPs in the liver, positron 
emission tomography (PET) imaging has been used to visualize OATP-mediated hepatobiliary 
transport in humans 171, rats 172 and mice 173. Cynomolgus monkeys share more than 90% of gene and 
amino acid sequence identity for human OATP1B transporters 15,49,174. Therefore, cynomolgus 
monkeys have been assessed as a more human-like model to study OATP1B-mediated DDIs. They 
have been used to study the inhibitory potential of cyclosporin A and DDIs reported for rosuvastatin 
175, pitavastatin and atorvastatin 174. These studies concluded that there is a need using several probe 
substrates and a pre-incubation step when performing in vitro inhibition studies 174. This also 
emphasizes how difficult the task is when we want to extrapolate in vitro data to more relevant in vivo 
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processes. Not only due to species differences in tissue localization and substrate recognition but also 
due to interindividual differences in dosing, tissue exposure and mechanisms involved in drug 
clearance. 
There are exceptional reviews on the in vitro-in vivo extrapolation of OATP-mediated DDIs: Chu et al., 
2012 49 and Ufuk et al., 2018 wrote excellent summaries on interspecies differences and DDIs and 
Shen et al., 2016 assessed Coproporphyrins I and III as probes for OATP1B1 176. 
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Chapter II 
Expression of Human Organic anion transporting polypeptides in 
insect cells reveals that sodium fluorescein is a general OATP 
substrate 
(The work presented in this chapter has been published in Biochemical Pharmacology (2015) 136) 
2.1 Abstract 
Organic anion transporting polypeptides (OATPs) are plasma membrane proteins encoded by the 
SLCO gene family. OATPs are sodium‐and ATP- independent transporters mediating the uptake of 
a wide variety of amphipathic or negatively charged compounds 45. There are 11 human members, and 
two of them -OATP1B1 and OATP1B3- have been extensively studied in the past decade 56,78,177,178. 
Besides their physiological importance in the hepatic reuptake of bile acids and bilirubin, they are also 
influencing drug disposition/pharmacokinetics and are sites of DDIs 47,78. In addition, extensive 
research shows altered expression patterns in multiple cancer types for several other OATPs (see 
overview in Chapter I). Due to the reasons mentioned above, regulatory agencies, as the US Food and 
Drug Administration (FDA) and the European Medicines Agency (EMA) and the International 
Transporter Consortium recommend determining the relative contribution of certain OATPs (e.g.: 
OATP1B1 and OATP1B3) to in vivo pharmacokinetics of drugs 179,180. Even though there is a growing 
interest, most members of the family remain poorly characterized, owing to the limited availability of 
test substrates and functional assays and lack of suitable expression systems with well-defined protein 
expression. 
The existing preclinical models designed to typify the OATPs’ substrate profile rely on mass 
spectrometry (MS) or radioactive test substrates such as tritiated estrone-3-sulfate, bromosulfophtalein 
and estradiol-17β-glucuronide 127,181. Although these methods proved to be excellent tools for initial 
small-scale transporter-drug interaction tests, they are not suitable for larger-compound screenings 
given their cost and time requirements, and limited substrate availability. Substantial efforts have been 
made to develop fluorescent probes to substitute radioactive labeling since they are sensitive, 
affordable and carry a potential for scaled-up automated compound discovery. For instance, sodium-
fluorescein (Na-fluo), fluorescein-methotrexate (Fl-MTX), indocyanine green and fluorescent bile 
acids were identified previously as fluorescent substrates for OATP1B1 and/or OATP1B3 
131,132,134,149,182, but none were available for other members of this family. Moreover, there is no known 
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substrate for OATP6A1. Thus, there is a significant gap in the ability to predict OATP-mediated drug 
disposition.  
Therefore, in this chapter, I describe a new fluorescence-based functional assay that can be used to 
study the function of human OATPs. We expressed all 11 human OATPs in a baculovirus-infection 
based insect cell system and measured the accumulation of Na-Fluo or Fl-MTX. We measured time- 
and concentration-dependent, and inhibitor sensitive uptake of these compounds. Moreover, we 
demonstrated that an acidic extracellular microenvironment led to a stimulation of substrate transport. 
We found that Na-Fluo is a pan-OATP substrate, while Fl-MTX can only be transported by OATPs, 
1A2, 1B1, 1B3 and 2B1. We also identified new molecular interactions between OATP2B1 and 
Imatinib, OATPs, 3A1, 5A1 and 6A1 and estradiol-17β-glucuronide, and OATPs, 1C1 and 4C1 and 
prostaglandin E2. 
Na-fluorescein is the first fluorescent substrate that can be used to characterize the entire human 
OATP family and the insect-cell based assay is a useful tool to identify OATP substrates. This system 
might help to elucidate structure-function relationships, predict interactions of pre- and clinical drugs 
which could lead to better dosage guidelines and less drug-related toxicity. 
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2.2 Materials and methods 
2.2.1 Materials 
Cholic acid (CA), glycocholic acid (GC), propidium iodide, prostaglandin E2 (PGE2), rifampicin (Rif), 
sodium fluorescein salt (Na-Fluo), taurocholic acid (TC) and ursolic acid (UA) were purchased from 
Sigma–Aldrich (Budapest, Hungary). Fluorescein-methotrexate (Fl-MTX) was obtained from 
Biotium, Inc. (Hayward, CA, US). Restriction endonucleases were from New England Biolabs, Ltd. 
(Ipswitch, MA, US) 
2.2.2 Plasmid constructs 
To generate the plasmids carrying the gene of human OATPs, we first tailored unique restriction sites 
that enabled us to insert the gene of each human OATP into the baculoviral transfer vector pAcUW21 
(BD Biosciences, San Jose, CA, US). The modified plasmid, termed pAcUW-L2, was constructed by 
inserting oligonucleotide linkers between the BamHI and NotI sites of pAcUW21-L/ABCG2, a 
vector generated previously in our lab 183.  
5`-GGCCGTGAATTCGGTACCTCGAGCTCGCGGCCGCT-3` 
5`-GATCAGCGGCCGCGAGCTCGAGGTACCGAATTCAC-3` 
Full-length cDNA sequences encoding human OATPs were then introduced into pAcUW-L2 using 
the appropriate restriction sites. cDNAs of OATPs, 1A2, 1B3, 1C1, 2A1, 2B1, 4A1, 5A1 and 6A1 
were obtained from the Harvard PlasmID Repository (Harvard Medical School, Boston, MA, US), 
and the cloning of OATP1B1 (Gene ID: AB026257), OATP3A1 variant 1 (AB031050) and OATP4C1 
(353189) was performed using the previously constructed vector, pSPORT1 23,139. OATP1B1 and 
OATP3A1 transfer vectors were constructed by isolating the corresponding full-length OATP cDNA 
from pSPORT1, and then subcloning into the pAcUW21-L2 plasmid between the KpnI and NotI 
restriction endonuclease sites. Sequence analysis revealed that the OATP1B1 cDNA encodes a 
polymorphism (N130D, rs2306283), therefore, we reverted the sequence to wild-type (Q9Y6L6.2) 
using site-directed mutagenesis. The primers used in the mutagenesis reaction were: 1B1-N130N for 
5`-ACTAATATCAATTCATCAGAAAATTCAACA-3`, 1B1- N130N rev 5`-
TGTTGAATTTTCTGATGAATTGATATTAGT-3`. To generate the OATP6A1 construct, the 
corresponding cDNA was removed from a pBluescriptR vector (BC034976, HsCD00333181) using 
NotI and BamHI restriction enzymes, and subcloned into pAcUW21-L/ ABCG2. Sequencing 
revealed that the vector HsCD00333181 contains a shorter isoform of 6A1, which is missing amino 
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acids 206–267, compared to the canonical sequence (Q86UG4-1). The cDNA corresponding to the 
missing region was synthesized by ShineGene Molecular Bio-Technologies, Inc. (Shanghai, China), 
and subcloned into the pAcUW-21-L/OATP6A1 isoform 2 vector between the NdeI and SpeI sites. 
The open reading frames of OATP1A2 (BC042452, HsCD00333163), OATP1B3 (BC141525, 
HsCD00348132), OATP1C1 (BC022461, HsCD00332885), OATP2A1 (BC041140, 
HsCD00338568), OATP2B1 (BC041095.1, HsCD00378878), OATP4A1 (BC015727, 
HsCD00334491), OATP4C1 and OATP5A1 (BC137424, HsCD00342690) were amplified by HF 
PCR (Phusion® High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) following the manufacturer’s 
instructions and using the following primers: 
1A2  for 5`-GGAAGATCTGCGGCCGCGCCACCATGGGAGAAACTGAGAA-3`  
rev 5`-ATTGAGCTCCTGCAGTTACAATTTAGTTTTCAAT-3` 
1B3  for 5`-GTAAATGCGGCCGCAACTCGAGGCCACCATGGACCAACATCAACAT-3` 
rev 5`-GTACATGCGGCCGCACTGCAGTTAGTTGGCAGCAGCATT-3` 
1C1  for 5`-TGTTTAAACTCTAGAGCCACCATGGACACTTCATCCAAAGAA-3` 
rev 5`-TAACCTGCAGGCGGCCGCGTTTCTAAAGTTGAGTTTCCTTG-3 
2A1  for 5`-GTAAATGCGGCCGCAAGAATTCGCCACCATGGGGCTCCTGCCCA-3`  
rev 5`-GTACATGCGGCCGCTAAGCTTTCAGATGAGGCCTGCCGC-3` 
2B1  for 5`-GTAAATGCGGCCGCAAGAATTCGCCACCATGGGACCCAGGATAGG-3` 
rev 5`-GTACATGCGGCCGCTAAGCTTTCACACTCGGGAATCCTC-3` 
4A1  for 5`-GGAAGATCTGATATCGCCACCATGCCCCTGCATCAGCTG-3`  
rev 5`-ATTGAGCTCAAGCTTTCAGACGCTGCTCTGGAG-3` 
4C1  for 5`-GGAAGATCTGCGGCCGCGCCACATGAAGAGCGCCAAAGGT-3` 
rev 5`-ATTGAGCTCAAGCTTTCACCCTTCTTTTACTAT-3` 
5A1  for 5`-TGTTTAAACTCTAGAGCCACCATGGACGAAGGCACTGGACTGC-3` 
rev 5`-TAACCTGCAGGAGCGGCCGCCTTCTTCCATTTTCAAGCTTCAGGAGG-3` 
The amplified fragments were digested using the following restriction enzymes (OATPs, 1A2, 4A1 
and 4C1: BglII and SacI, OATP1B3: XhoI and NotI, OATP2A1 and OATP2B1: EcoRI and NotI, 
and OATP1C1 and OATP5A1: PmeI and NotI) and subcloned into the pAcUW21-L2 plasmid. 
Because sequencing of the OATP4A1 construct revealed that the purchased cDNA contains a known 
SNP of OATP4A1 (232G > A (V78I), rs1047099), the canonical sequence (Q96BD0-1) was generated 
via Quick Change mutagenesis using the following primers: 5`-AGGTGCGGTACGTCTCGG-3` 
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(4A1 for and 5`-CCGAGACGTACCGCACCT 30 (4A1 reverse). The DNA sequences for all 
constructs were verified by sequencing. 
2.2.3 Growth and maintenance of Sf9 insect cell line and generation 
of recombinant baculoviruses 
Spodoptera frugiperda (Sf9) cells were grown in suspension culture using TNM-FH insect medium 
(Sigma–Aldrich, Budapest, Hungary) supplemented with 10% fetal bovine serum (FBS), 100 units/ml 
penicillin and 100 mg/ml streptomycin, at 27°C. Recombinant baculoviruses, carrying the different 
human OATP cDNA sequences, were generated using the BaculoGold Transfection Kit (BD 
Biosciences, San Jose, CA, US) following the manufacturer's instructions. After amplification, the virus 
stocks were stored at 4°C. For the uptake experiments, we choose virus stocks giving the highest 
protein expression (after Western blot-based quantitation). 
2.2.4 Immunoblot analysis of OATPs  
Whole cell lysates of Sf9 cells (5–10 g) were separated on 7.5% Laemmli SDS-PAGE. Protein 
transfer to PVDF membrane was performed using the Bio-Rad mini Protean 3 system. Protein 
concentrations were determined using the Lowry method using BSA as standard. Membranes were 
incubated overnight with polyclonal antibodies. The antibodies used for the detection of OATPs, 1A2, 
1B1, 1B3, 1C1, 2B1, 3A1_v1 and 4A1 were provided by Bruno Stieger 23,44,139. Antibodies against 
OATP2A1 (HPA013742), OATP4C1 (HPA036516), OATP5A1 (HPA025062) and OATP6A1 
(HPA054126) were purchased from Atlas Antibodies (Stockholm, Sweden). Antibody dilutions: 1:250 
for OATP5A1, 1:500 for OATPs, 1A2, 1B1, 2A1, 4C1 and 6A1, and 1:1000 for OATPs, 1B3, 1C1, 
2B1, 3A1_v1 and 4A1. After O/N incubation, PVDF membranes were incubated with 10,000–
20,000x diluted, HRP-conjugated anti-rabbit secondary antibodies (Jackson ImmunoResearch, 
Suffolk, UK) for 1h. Luminescence was detected using the Luminor Enhancer Solution kit by Thermo 
Scientific (Waltham, MA, US). 
2.2.5 Cell-based dye uptake assay and measuring OATP transport 
activity 
OATP-transduced Sf9 cells were harvested 40 h post infection into one of the following buffers: 
Buffer pH 7.4–8.4: 125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 12 mM MgSO4, 
25 mM HEPES, and 5.6 mM glucose, with the pH adjusted to 8.4 or 7.4 using 10 N NaOH or 10 N 
HCl, respectively. Buffer pH 4.5–7.4: 125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 
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12 mM MgSO4, 25 mM MES, and 5.6 mM glucose, with the pH adjusted to 7.4, 6.5, 5.5 or 4.5 using 
10 N NaOH or 1 M HEPES. 
Cells (2–5 x105/reaction) were pre-incubated in the presence or absence of inhibitors for 5 min at 
37°C. The reaction begun with the addition of two times concentrated Fl-MTX or Na-Fluo to a final 
concentration of 1 µM except for the measurement of concentration dependence. Uptake was stopped 
after 10 min (unless stated otherwise) of incubation at 37°C by adding 1 ml of ice-cold phosphate-
buffered saline. The cells were kept on ice until flow cytometry analysis. The cellular fluorescence of 
10,000 live cells was measured by an Attune® Acoustic Focusing Cytometer (Applied Biosystems, 
Life Technologies, Carlsbad, CA, US) at an excitation wavelength of 488 nm and an emission 
wavelength of 530 nm. Dead cells were excluded by propidium iodide (1 µg/ml) staining. As a control, 
we used Sf9 cells expressing a Drosophila melanogaster telomerase subunit (the plasmid encoding this 
nuclear protein was a generous gift from Dr. Imre Boros at the Biological Research Center in Szeged, 
Hungary). Transporter activities were calculated by subtracting the background fluorescence 
(measured in control cells) from fluorescence measured in Sf9 cells expressing human OATPs. Each 
data point represents the mean of at least 3 independent experiments. 
2.2.6 Data analysis 
Kinetic parameters of dye uptake were calculated using non-linear curve fitting (Hill fit) and Graph 
Pad Prism 8 software. A Student’s t- test was used to calculate any statistical significance. The p-value 
for statistical significance was set at 0.05 (*), 0.01 (**) or 0.001 (***). 
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2.3 Results 
2.3.1 Baculovirus-infection based insect cells are suitable to express 
functional human OATP1B1 and OATP1B3 
Sf9 insect cells were derived from the pupal ovarian tissue of the fall army worm (Spodoptera frugiperda). 
This cell line provides the host for the baculovirus-based expression system. Sf9 cells have been used 
to express various human proteins for more than 20 years 184. Some of the main advantages of this 
system, compared to mammalian cell lines are time- and cost efficiency and higher protein expression 
levels. Moreover, if compared to prokaryotic expression systems, some human proteins require post-
translational modifications to be functionally active (like phosphorylation, disulfide bond formation, 
N-and O-linked glycosylation and signal peptide cleavage which has an impact on the protein folding). 
This system provides an excellent platform to express and study the function of membrane transporter 
proteins (e.g. ABC-transporters) 185–188. Interestingly, except for OATP2B1, this  system to study 
human OATPs has not yet been described 151. The baculovirus-insect cell system has a transient nature, 
hence viral infection results in cell lysis after time giving its minor flaw. However, carefully measuring 
the viability and the protein levels following infection, it has been previously demonstrated that, 25-
30 % of the cells 36-40h post-infection still have intact plasma membranes and they expressed the 
protein of interest near to the maximum levels 183. 
To test the applicability of this system to study human OATPs, first we expressed the two best 
characterized members of the family, OATP1B1 and OATP1B3 in Sf9 cells. Fig.2.1 shows the 
successful expression of these proteins in Sf9 cells.  
Figure 2.1 Immunodetection of OATP1B1 and OATP1B3 expressed in Sf9 cells. 5 µg whole-cell lysates 
were separated on 7.5%SDS gels and then transferred to PVDF membranes. The membranes were incubated 
in milk with anti-OATP1B1 (1:500) and anti-OATP1B3 (1:1000) polyclonal antibodies. HRP-conjugated, 
polyclonal anti-rabbit secondary antibody was used in a 1:10000 dilution. Control (ctr.) shows Sf9 cells 
overexpressing an unrelated protein. 
Next, we tested the functionality of OATP1B1 and OATP 1B3. 40 hours after infection, we measured 
the cellular accumulation of two previously described substrates, Na-Fluo and Fl-MTX. We could 
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selectively measure the uptake of Na-Fluo and Fl-MTX in intact cells expressing OATP1B1 or 
OATP1B3 by flow cytometry (see Figure 2.2). This technique enabled us to exclude potential false 
positives, such as dead cells with compromised membranes by propidium iodide co-staining.  
 
Figure 2.2 1 µM fluorescein methotrexate (Fl-MTX) and 1.5 µM sodium fluorescein (Na-Fluo) uptake 
in Sf9 cells overexpressing OATP1B1 or OATP1B3 in the presence or absence of 20 µM cyclosporin A 
(CsA).The transport was measured for 10 min at 37°C and pH 7.4. Dead cells were excluded based on 
propidium-iodide positivity. Figure was published in 136. 
The transport of the fluorescent compounds was rapid, showed saturation kinetics and could be 
inhibited with a known inhibitor, cyclosporin A (CsA) 112 as shown on Figure 2.3 for Fl-MTX. The 
transport showed similar kinetics for sodium-fluorescein (see Figure 2.4).  
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Figure 2.3 Time- and concentration-dependent accumulation of Fl-MTX in Sf9 cells expressing 
human OATP1B1 or OATP1B3 measured by flow cytometry. Upper panel: 1 µM Fl-MTX was added and 
cellular fluorescence was measured for 0.5-20 min at 37°C, pH 7.4 in the presence or absence of 20 µM 
Cyclosporin A (CsA). Lower panel: concentration-dependent accumulation of Fl-MTX after 2 min incubation 
with the substrate. Figures show geomean fluorescence measured by flow cytometry. Data points represent the 
average of at least three independent measurements ±SD values.  
























































Figure 2.4 Time- and concentration dependent accumulation of sodium-fluorescein in Sf9 cells 
expressing human OATP1B1 or OATP1B3. Upper panel: 1 µM Na-Fluo was measured between 0.5-20 
min at 37°C, pH 7.4. Lower panel: concentration-dependent accumulation of Na-Fluo after 4 min incubation 
with the substrate at 37°C, at pH 7.4. Figures show geomean fluorescence measured by FACS (background 
fluorescence was subtracted based on fluorescence measured in cells expressing an unrelated protein). Data 
points represent the average of at least three independent measurements ± SD values.  
Kinetic parameters of the transports are summarized below for both substrates. The OATP-mediated 
uptake was absent at 4°C (data not shown). Comparing these data with the in vitro results obtained 
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  Na-Fluo Fl-MTX 
Protein OATP1B1 OATP1B3 OATP1B1 OATP1B3 
t 1/2 (min) 6.71±2.33 5.58±0.11 2.64±0.53 4.16±0.28 
Km (µM) 25.73±4.68 38.55±15.00 0.23±0.04 0.53±0.4 
Table 2.1 Kinetic parameters of Na-Fluo and Fl-MTX transport 
measured in Sf9 cells expressing OATP1B1 or OATP1B3. 
In order to further validate and characterize OATP1B1/1B3-mediated transport in Sf9 cells, we tested 
the inhibitory effect of several previously described OATP-interacting compounds on the uptake of 
Na-Fluo and Fl-MTX (Figure 2.5). Most of the tested inhibitors attenuated OATP1B1/1B3 mediated 
transport, confirming that the overexpressed proteins are indeed fully functional and that these dyes 
can be applied to detect OATP1B1/1B3 drug interactions. OATPs are thought to have multiple 
binding sites which might explain the observed differences in the inhibition of the two fluorescent 
compounds 45. 
Figure 2.5 OATP1B1 and OATP1B3-mediated Fl-MTX and Na-Fluo transport in Sf9 cells. A panel of 
OATP-interacting compounds was assessed for 1 µM Fl-MTX and 1 µM Na-Fluo transport activity for 10 min 
at 37°C and pH 7.4. Transporter activity shown as percentage of control: which was baseline uptake measured 
with Na-fluo or Fl-MTX alone (100%) after corrected for the uptake by control cells. Bars represent averages 
of at least 3 independent measurements (±SD). nt: non-treated control, CsA: 20 µM cyclosporin A, UA: 20 
µM ursolic acid, CA: 150 µM cholic acid, GC: 150 µM glycocholate, TC: 150 µM taurocholate, EG: 50 µM 
estradiol-17β-glucuronide, PGE2: 5 µM prostaglandin E2, Rif: 10 µM rifampicin, and MTX: 10 µM 
methotrexate. Significance: *p < 0.05, **p < 0.01, ***p < 0.001 
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2.3.2 Expression of the human OATP family in insect cells reveals 
sodium fluorescein as a pan-OATP substrate 
After successfully showing that the insect cell-based system is, indeed, useful for the functional 
expression of OATP1B1 and OATP1B3, our next aim was to express all human OATPs in Sf9 cells. 
The protein levels of OATPs; 1A2, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 5A1 and 6A1 were determined by 
Western blot (see Figure 2.6). Based on the predicted size of the proteins we assumed that the bands 
in our blots correspond to the core-glycosylated form of our overexpressed proteins 165. Glycosylation 
in insect cells is not complete compared to mammalian cell lines. Although N-glycosylation in Sf9 cells 
results in simple oligo-mannose sugar chains, the glycoprotein will lack complex sugar groups with 
terminal sialic acids 189. However, it has been previously demonstrated for many membrane 
transporters, that this system produces proteins with relevant biological functions 151,187,190–192. 
Therefore, it is a suitable system for functional transporter studies. 
 
Figure 2.6 Human OATPs overexpressed in Sf9 cells. Whole cell lysates were loaded onto 7.5% Laemmli 
gels. 5 µg protein was loaded for OATPs, 1C1, 2B1, 4A1, 4C1 and 10 µg for OATPs, 1A2, 2A1, 3A1, 5A1 and 
6A1. Control (ctr.) represents Sf9 cells expressing an unrelated protein.  
To see if there is an interaction between other human OATP family members and the fluorescent 
OATP1B1/1B3 substrates, we measured Fl-MTX and Na-Fluo transport under the same conditions 
as we have optimized for OATPs, 1B1 and 1B3 (10 min incubation at 37°C, pH 7.4, using 1 µM 
fluorescent substrate). In these experiments, Fl-MTX was transported only by OATP1B1 and 
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OATP1B3, but surprisingly, all members of the hOATP family were able to show uptake of Na-Fluo 
(see Figure 2.7) 
 
Figure 2.7 Sf9 cells overexpressing human OATPs (see axis x) or an unrelated protein (ctr.). Cells were 
incubated with 1 µM Na-Fluo (upper panel) or 1 µM Fl-MTX (lower panel) at 37°C for 10 min at pH 7.4. 
Intracellular fluorescence was measured by flow cytometry. Graphs show geomean fluorescence, bars represent 
the average of at least three independent experiments ±SD values. Significance: *p < 0.05, **p < 0.01, ***p < 
0.001. 
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2.3.3 Effect of the pH on Na-fluorescein and Fl-MTX transport 
The transport mechanism of OATPs is not completely understood, but they`ve been shown to be 
organic anion exchangers. This is based on existing data showing that substrate transport is 
accompanied by the extrusion of bicarbonate or glutathione 155. Also, several papers were published 
on the pH dependency of OATPs, demonstrating that a low extracellular pH may lead to an increase 
of substrate transport by all human OATPs, and Rat Oatp1a1 and Oatp1b2 1,40,140,193. Therefore, we were 
interested to see, how the pH influences Fl-MTX and Na-Fluo transport in insect cells. Sf9 cells are 
grown at pH 6.2 which might intercept the optimal H+ gradient formation to facilitate the pH-sensitive 
OATP-driven transport. Thus, we tested various buffers adjusted to different pH values, ranging from 
pH 4.5 to 8.5 in Sf9 cells expressing either OATP1B1 or OATP1B3. Uptake of Fl-MTX and Na-Fluo 
by OATPs, 1B1 and 1B3 showed distinct pH dependence. As shown on Figure 2.8 Na-Fluo transport 
was significantly higher under acidic assay conditions, supporting the concept of a proton gradient-
driven uptake mechanism. It is important to note here, that the fluorescence intensity peak of Na-
Fluo reduces as the pH is lowered 137,138, therefore the observed increase in transport was due to the 
increased OATP1B1 or OATP1B3-mediated uptake not due to increased fluorescence of the dye. As 
I summarized in Chapter I, different theories are trying to explain how the pH might have a stimulatory 
effect on OATP function. One possible explanation is a change in the protonation levels either in the 
substrate itself or in amino acids (more precisely the conserved His) of the binding pocket of the 
transporter, which will change the affinity toward the substrate and result in increased uptake 43. 
Fluorescein has a carboxyl and a phenol group which can be ionized. As the pH changes, it could 
become a cation (pH 1), a neutral quinonoid or lactonoic (pH 2-4), a monoanion (pH 5) or a dianion 
(≥pH 6.4) molecule. Hence, in the case of fluorescein we expect a neutral molecule at pH 4.5, a 
monoanion at pH 5.5 and a dianion above 6.4. While the conserved His (pk=6) would be protonated 
below pH 6. Hence the observed phenomenon can be attributed to the changes in the charge of the 
substrate; however, it does not fit in any of the existing mechanisms of OATP transport, e.g. the 
observed highest transport of the neutral fluorescein molecule at pH 4.5.  
Interestingly, Fl-MTX uptake showed less pronounced pH dependence, and in contrast to Na-Fluo 
maximal dye uptake could be observed at or close to neutral pH. In the case of fluorescein-
methotrexate, based on the calculated pKa values we expect a monoanion in the pH range between 
4.5 and 8, therefore we conclude that the conserved His may not be involved in the recognition of Fl-
MTX. 
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Figure 2.8 pH-dependent uptake of 1 µM Fl-MTX (upper panel) or 1 µM Na-Fluo (lower panel) in Sf9 
cells overexpressing OATP1B1 or OATP1B3.Transport was measured for 10 min at 37°C in uptake buffer 
where the pH ranged from 4.5 to 8.4. Data shows geomean values from three independent experiments ±SD 
values minus the background fluorescence detected in control cells. Significance: *p < 0.05 
Because we observed a significant enhancement in transporter activity under acidic assay conditions 
for Na-fluo, we also wanted to test the entire human OATP panel at acidic pH. The optimized assay 
conditions for Fl-MTX were between pH 6.5-7.4 and between pH 4.5-5.5 for Na-Fluo. To achieve 
maximum transport activity closer to physiologically relevant conditions (although local H+ gradients 
may be different), we choose to measure transport at pH 6.5 for Fl-MTX and pH 5.5 for Na-Fluo. 
Consistent with our previous results for OATP1B1 and OATP1B3, lowering the extracellular pH 
resulted in increased Na-Fluo transport by all human OATPs, despite the increased background 
fluorescence (Figure 2.9). However, when we measured Fl-MTX transport, only OATP1A2 and 

































































Figure 2.9 Na-fluorescein and Fl-methotrexate uptake in Sf9 cells expressing hOATPs. Cells 
overexpressing OATPs were incubated with 1 µM Na-Fluo at pH 5.5 (upper panel) or 1 µM Fl-MTX at pH 6.5 
(lower panel) for 10 min at 37°C. Data represents geomean values of the average of three independent 
measurements (±SD values). Significance: *p < 0.05, **p < 0.01, ***p < 0.001 
2.3.4 Effect of inhibitors on Na-Fluo and Fl-MTX transport 
Following our initial success in confirming that the insect-cell based system is suitable for expressing 
fully functional human OATPs, and then proving that Fl-MTX and Na-fluo are high affinity substrates 
for some of these transporters, we also wanted to use this platform to detect OATP interactions. 
Therefore, we choose a set of previously described OATP-interacting compounds and measured Na-
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Fluo transport in all 11 human OATPs in the presence of these drugs. As shown on Figure 2.10, the 
transport activity of each OATP could be altered by at least one compound. Cyclosporin A inhibited 
OATP-mediated Na-Fluo transport in cells expressing OATP1B3, OATP1A2, OATP2A1 and 
OATP2B1. Prostaglandin E2 decreased the Na-Fluo uptake in cells expressing OATP1A2, OATP1C1, 
OATP2A1, OATP2B1 and OATP4C1. Strikingly, estradiol-17β-glucuronide and ursolic acid 
enhanced the OATP-mediated transport for several members of the OATP family. 
 
Figure 2.10 Sodium-fluorescein uptake is changed by a variety of compounds. Sf9 cells were incubated 
with 1 µM Na-Fluo at pH 5.5 for 10 min in the presence of estradiol-17β-glucuronide, ursolic acid, cyclosporin 
A or prostaglandin E2. Baseline Na-Fluo uptake represented as 100% (dashed line), columns are showing 
transporter activity altered by the OATP-interacting compound as a percentage of baseline fluorescence. 
Colored bars indicate newly defined interactions. Significance: *p < 0.05, **p < 0.01, ***p < 0.001 
The stimulatory effect of the compounds can be explained by allosteric activation or by co-transport. 
Allosteric activation was described earlier for OATP2B1 (where progesterone enhanced the 
OATP2B1-dependent pregnenolone sulfate transport) 194 and for OATP1B1 and OATP1B3 where 
pravastatin uptake was further stimulated by non-steroid anti-inflammatory drugs (NSAIDs) 195. 
Allosteric activation could be an important contribution to the transporter-mediated DDIs and 
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demonstrates that a drug doesn`t necessarily have to act as an inhibitor or substrate to modulate the 
transport activity. 
Additionally, as OATP1A2, OATP1B1 and OATP2B1 were able to transport Fl-MTX, we measured 
Fl-MTX accumulation in the presence of these previously described OATP-interacting compounds. 
As Figure 2.11 shows; cyclosporin A, ursolic acid, bile acids, prostaglandin E2, methotrexate and 
Imatinib inhibited the OATP-mediated Fl-MTX uptake.  
 
Figure 2.11 Fluorescein-methotrexate uptake inhibited by a variety of compounds. Sf9 cells were 
incubated with 1 µM Fl-MTX at pH 6.5 for 10 min in the presence of cyclosporin A (CsA), ursolic acid (UA), 
glycocholate (GC), taurocholate (TC), estradiol-17β-glucuronide (EG), prostaglandin E2 (PGE2), methotrexate 
(MTX) and Imatinib. Baseline Fl-MTX uptake values measured without the compounds represented as 100% 
(dashed line and nt). Columns show activity as a percentage of baseline uptake. Measurements were repeated 
at least 4 times, data shows average ±SD values. Colored bars indicate novel OATP-interactions.  
In summary, optimizing the assay conditions helped us to describe new interactions between OATPs 
and drugs or naturally occurring compounds (colored bars on Figure 2.10 and Figure 2.11). These 
findings are nice additions to the hitherto described OATP-interacting compounds. Furthermore, we 
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were able to show interactions for poorly characterized members of the OATP-family, such as 
OATP5A1 and OATP6A1. So far OATP5A1 was only demonstrated to transport quercetin 120, but 
with our functional assay, we detected interaction with estradiol 17-β-D-glucuronide. OATP6A1, 
whose function and substrate profile remains unknown, showed altered Na-fluorescein uptake in the 
presence of estradiol-17β-glucuronide and ursolic acid (pentacyclic triterpenoid found in fruit rind). 
2.4 Discussion 
There is growing evidence that OATPs are important contributing factors in drug disposition and 
their function is also altered by widely marketed drugs. Given the absence of suitable functional assays, 
most members of the human OATP family remain poorly characterized. So far, the main hurdles have 
been the limited availability of radioactively- and fluorescently labeled substrates and the lack of cell-
based models to investigate OATP-function. In this current study, we established an insect cell-based 
fluorescent transport assay which is suitable for the functional expression of all human OATPs and 
for OATP-drug interaction screens.  The main benefit of using insect cells compared to mammalian 
expression systems is the relatively high level of protein expression levels, therefore lower background 
transporter activity. Although OATP2B1 expressed in insect cells was shown to transport [3H] 
estrone-3-sulphate before (Tschantz et al., 2008) 151, our assay provides the first comprehensive system 
to express all human OATPs. It is important to emphasize before we highlight the main advantages 
of this system; with this approach, our target proteins are transiently expressed and the baculovirus 
infection eventually leads to the death of our cells. However, choosing the right time point where the 
cells are still viable and our protein is expressed in high levels, we can measure the OATP-mediated 
intracellular accumulation of fluorescent test substrates. One could also argue that the proteins 
expressed in the Sf9 insect cell system are only core glycosylated 165, therefore they might not be fully 
functional. To assess this concern, we used known OATP substrates to test the transport activity of 
OATP1B1 and OATP1B3, the two best-characterized members of the family. They both showed 
saturable, inhibitor sensitive uptake of Na-fluorescein and fluorescein-methotrexate (Figure 2.3, 2.4 
and 2.5) comparable to the data measured in mammalian cells 131,132 further validating the applicability 
of this method. 
Using the same expression system has its unique advantage; it allows a systemic comparative study of 
OATPs without having to consider the varying assay conditions and the different cellular models used 
by other laboratories.  
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The pH-sensitive transport activity of human OATPs was proven by several other groups in the past. 
Being able to respond to changes in the microenvironment might be a way to regulate transporter 
function. We also investigated the pH-dependent transport activity of OATP1B1 and OATP1B3 and 
we found that the optimal condition for Fl-MTX transport is at pH 7.4, while Na-Fluo transport is 
increased with an acidic extracellular milieu (Figure 2.7, 2.8 and 2.9). Other OATPs exhibited lower 
Na-Fluo transport at neutral pH. However, they all showed a significant increase in Na-Fluo uptake 
at pH 5.5, further demonstrating that Na-Fluo is a pan-OATP substrate. Fl-MTX transport is less 
affected by changing the pH. There are attempts to explain why a low extracellular pH could influence 
transporter activity. OATPs (except OATP1C1) have a conserved pH-sensitive histidine (His) in the 
3rd transmembrane domain which could serve as a pH sensor. Leuthold et al. demonstrated that the 
transport activity of OATP1C1 lacking this His is not activated by  acidic pH 40. In contrast to this, in 
my work OATP1C1-mediated Na-Fluo transport was activated by a lower proton gradient. In 
addition, the most recent publication of our laboratory also showed an increased transport of the 
fluorescent viability dye Live or Dye 488 by OATP1C1 at pH 5.5 compared to pH 6.5 or 7.4 140. 
Therefore, pH may have various influence on the transport depending on the substrate used.  
The primary goal for less-characterized OATP-family members would be the identification of 
physiological substrates and exogenous compounds that might interfere with their function. Our 
functional assay may serve as a new tool to achieve this goal. Here we have shown this system is 
suitable for the identification of new substrates and molecular interactions. We validated our assay by 
reconfirming previously published interactions between OATP1A2, OATP1B1, OATP1B3 and 
OATP2B1 with bile acids, cyclosporin A, prostaglandin E2 and methotrexate (Figure 2.5, 2.10 and 
2.11). Moreover, we also identified new molecular interactions between ursolic acid and OATP1A2, 
OATP2A1, OATP3A1, OATP4A1 and OATP6A1, cyclosporin A and OATP2A, estradiol-17β-
glucuronide and OATP3A1, OATP5A1 and OATP6A1, prostaglandin E2 and OATP1C1 and 
OATP4C1 (Figure 2.10 and 2.11). These findings might suggest new roles in hormone transport for 
OATPs, 3A1, 5A1 and 6A1. As OATPs show ectopic expression in several tumors they might affect 
the survival of hormone-dependent tumors 64. 
This assay also revealed surprising interactions. Contrary to De Bruyn et al., we saw significant 
OATP2B1-mediated Na-Fluo transport at pH 7.4 131 (Figure 2.7). Interestingly, Na-Fluo transport at 
pH 5.5 in OATP1B1 was stimulated rather than inhibited by cyclosporin A, estradiol-17β-glucuronide, 
prostaglandin E2 and ursolic acid (Figure 2.10). This effect appears to be pH-specific, as these 
compounds inhibited Na-Fluo uptake at pH 7.4 (Figure 2.5). In other experiments, we observed a 
Page | 50  
 
similar, pH-dependent stimulation in Fl-MTX transport by several known interacting compounds 
(data not shown). Correspondingly, we saw a similar activating effect by estradiol-17β-glucuronide on 
OATP3A1, 5A1, 6A1-mediated Na-Fluo transport activity, and ursolic acid on OATP3A1, 
OATP4A1, OATP4C1 and OATP6A1 transport (Figure 2.10). This data suggests that transport 
activity is allosterically controlled, as previously documented for OATP1B3 and OATP2B1 194,195.  
However, it is important to point out that our system cannot reveal the true mechanism of this 
substrate-dependent interaction even though several compounds can seemingly inhibit or stimulate 
the uptake of our test substrates with different degrees of interaction. This might be explained by the 
level of interaction between the compounds and OATPs’ two binding sites 132. Consequently, the 
transport of the potential substrates should be tested by direct transport measurements e.g. by using 
mass spectrometry or radioactively labeled substrates.  
In summary, we developed a new cell-based assay which can be used to express human OATPs and 
may be applicable for inhibitor and substrate screening and to assess risk for possible drug-drug 
interactions. It might also be a new tool to compare pharmacologically relevant OATP variants and 
elucidate structure-function relationships.  
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Chapter III 
Identification of novel cell-impermeant fluorescent substrates for 
testing the function and drug interaction of Organic anion 
transporting polypeptides, OATP1B1/1B3 and 2B1 
(The majority of work presented in this chapter has been published in Patik et al., Scientific Reports 
(2018)142) 
3.1 Abstract 
OATP1A2, OATP1B1, OATP1B3 and OATP2B1 have been shown to have multispecific transport 
capabilities as they transport not only endogenous substrates (bile acids, bilirubin and hormones) but 
a wide range of pharmacologically relevant compounds (e.g. statins, antibiotics, antivirals and 
chemotherapeutics). OATP1B1 and OATP1B3 are known to mediate drug-drug and drug-food 
interactions, leading to altered pharmacokinetics and unexpected toxicity; while the pharmacological 
role of the ubiquitously expressed OATP2B1 is less well characterized.  
Testing the interaction between a new molecular entity and OATP1Bs is recommended at the initial 
stages of drug development. In broad terms, the strategy to study OATPs has been based on 
radiolabeled substrates. However, radioactive isotopes are continuously challenged by a new 
generation of fluorescent labels. Fluorescent substrates eliminate the hazards associated with the use 
of radioactive compounds, the resulting laboratory waste doesn’t require special disposal, therefore it 
is safer to use. Fluorescent substrates are better suited for OATP-drug screens; even more in high-
throughput setups, given their relatively low cost, similar or even higher sensitivity and greater 
flexibility in multicolor labeling. 
There were attempts to set up fluorescent substrate-based transport assays to measure OATP1B1 and 
OATP1B3 transport function and drug interactions 55,131,196; however, these do not necessarily meet 
high-throughput drug screening criteria, and a fluorescence-based screening assay for OATP2B1 is 
entirely missing. 
The following research provides an alternative framework to study OATP-drug interactions. We 
describe novel, pH-independent, fluorescent substrates for OATP1B and OATP2B1 with minimal 
passive cellular uptake and high signal to noise ratio. We show the OATP-mediated uptake of 
commercially available fluorescent dyes including Zombie Violet, Live/Dead Violet, Live/Dead 
Green, Cascade Blue and Alexa Fluor 405. The uptake measured in cells expressing hepatic OATPs 
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are time and concentration-dependent and sensitive to inhibitors. Furthermore, our results strongly 
suggest that Live/Dead Green can be utilized for OATP function-based sorting. This method could 
be a new tool for the selective enrichment of OATP proteins in different cell lines. 
The fluorescence-based transport assay measuring the uptake of the best-performing substrates opens 
the way to the development of sensitive high-throughput assays for the detection of OATP drug 
interactions. Development of experimental strategies such as this may assist in explaining different 
aspects of OATP function and help gaining a deeper and more comprehensive understanding of the 
pharmacokinetics of drugs.  
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3.2 Materials and methods 
3.2.1 Materials 
Fluorescent dyes: Zombie dyes (Violet and Green) were bought from Bio Legend® (San Diego, CA, 
US). LIVE/DEAD® Fixable Cell Stain Dye panel, Cascade Blue hydrazide, Alexa Fluor 405 
succinimidyl ester were bought from Thermo Fischer Scientific (Waltham, MA, US), and fluorescein-
methotrexate triammonium salt from Biotium (Hayward, CA, US). Restriction endonucleases were 
from New England Biolabs Ltd. (Ipswitch, MA, US). All other materials, if not indicated otherwise, 
were purchased from Sigma Aldrich, Merck (Budapest, HU). 
3.2.2 Generation of plasmid constructs 
Generation of baculovirus expression vectors (pAcUW21-L/OATP and pAcUW21-control) was 
described in Chapter II. OATP2B1 expressing cells were generated with transposase mediated 
genomic insertion of the OATP2B1 cDNA (BC041095.1, HsCD00378878). OATP2B1 cDNA was 
amplified (Phusion1 High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) from the vector ordered from 
Harvard PlasmID Repository (Harvard Medical School, Boston, MA, US) by using the following 
primers: forward 5′: GTAAAT GCGGCCGC AA GAATTC GCCACCATGGG 
ACCCAGGATAGG and reverse 5′ GTACAT GCGGCCGC T AAGCTT 
TCACACTCGGGAATCCTC. The PCR fragment was cloned between the NotI-HindIII sites of the 
pSB-CMV vector 197.The cDNAs of OATP1B3-V1 and OATP1B3-ct were amplified by HF PCR 
from the pAcUW21-L/OATP1B3wt vector using the following forward primers: 
 5′ ACTAGTTTAAACGCCACCATGTTCTTGGCAGCCCTG (OATP1B3-V1), 
ACTAGTTTAAACGCCACCATGAAAATTTCCATCACT (1B3-ct) and reverse primer 5′ 
GTACATGCGGCCGCACTGCAGTTAGTTGGCAGCAGCATTGTC. After digestion with PmeI 
and PstI restriction enzymes the PCR fragments were cloned to the corresponding sites of the pRRL-
CMV-MCS-IRES-ΔCD4 vector (). The base order of the cDNAs in all constructs was verified by 
sequencing. 
OATP1B1 and OATP1B3, OATP1B3 V1 overexpressing mammalian cells were created by lentivirus 
transduction. The lentiviral vector (pRRL-CMV-MCS-IRES-ΔCD4) was generated by replacing the 
GFP sequence with a multicloning site of the pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene #12252) 
plasmid (Didier Trono, Lausanne, Switzerland). An IRES (Internal ribosome entry site) was cloned 
between the PmlI and XbaI sites of the MCS (forward: 5′-
ACACGTGTCCGGACTAGTCCACCTTGCC TTACACATGAAGAG, reverse: 5′-
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ATCTAGAATGATCAGCCATATTATCATCGTGTTTTTCAAAG). The plasmid also contains a 
truncated CD4 receptor sequence enabling to monitor the virus transfection. Truncated CD4 cDNA 
was PCR amplified by the following primers (based on Liu et al. 198: 5′-
GATTCTAGAGCCACCATGAACCGGGGAGTCCCTTTTAGGC and 5′-
GTAGTCGACTTAGCGCCTTCGGTGCCGGCAC from the pCMV-SPORT6-CD4 (Harvard 
Plasmid Repository). After digestion with XbaI-SalI enzymes, the PCR fragment was cloned to the 
corresponding sites of the pRRL-CMV-MCS-IRES vector. The open reading frames of OATP1B1 
(Gene ID: AB026257) and OATP1B3 (BC141525, HsCD00348132) were amplified by HF PCR 
(Phusion1 High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) from the pAcUW-21-L/ OATP1B1-wt 
vector and from the plasmid obtained from Harvard PlasmID, respectively, using the following 
primers: OATP1B1: forward 5′ TATTATTCGAAGCCACCATGGACCAAAATCAACAT, reverse 
5′ CATGTAACTAGTTTAACAATGTGTTTCACTATCT. OATP1B3: forward 5′ 
ACTAGTTTAAACGCCACCATGGACCAACATCAACAT and reverse 5′ 
GTACATGCGGCCGCACTGCAGTTAGTTGGCAGCAGCATTGTC. After cleaving with BstBI 
and SpeI (OATP1B1) or PmeI-PstI (OATP1B3) the PCR fragments were cloned to the corresponding 
sites of the pRRL-CMV-MCS-IRES-ΔCD4 vector. The sequence of the cDNAs in the final vector 
was verified by sequencing. Empty vectors (pSB-CMV and pRRLdCD4) were used as negative 
controls (indicated as mock on the figures). 
3.2.3 Expression in insect cells 
Transient expression of human OATP1B1, OATP1B3 and OATP2B1 in Sf9 (Spodoptera frugiperda) 
cells was accomplished as described in Chapter II. Baculovirus infected Sf9 cell were collected 36–
40 hours post-infection and were used for transport measurements.  
3.2.4 Generation of mammalian cell lines. 
A431, MDCKII, HEK293T cells (ATCC) were transfected with 1 µg plasmid DNA (OATP2B1) + 
100 ng plasmid containing the transposase 197,199 using Fugene HD reagent (Promega, Madison, WI, 
US) following the supplier's protocol. 48 h following transfection, we added puromycin (1 µg/ml) to 
the media. After 14 days of selection with puromycin, cells were kept in DMEM (Gibco, Thermo 
Fischer Scientific, Waltham, MA, US) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C with 5% CO2 and 95% humidity, without 
puromycin. OATP1B1 and OATP1B3 overexpression in A431,HCT 8, HCT 116 cells were achieved 
by recombinant lentiviruses as described in Tatrai et al. 200. Briefly, HEK-293 T human embryonic 
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kidney cells (1.8 × 106 cells were plated onto 60mm X15mm Petri dishes) were transfected with (6 µg) 
pRRL-CMV-MCS-IRES-ΔCD4/OATP1B1 or OATP1B3, 2.2 µg pMDG and 4 µg psPax2 vectors200 
using CaPO4 precipitation. The supernatant, containing lentiviral particles was collected 72 h following 
transfection. Using the supernatant, A431, HCT 8 and HCT 116 cells were transfected with the virus. 
Cells were kept in DMEM (A431) or RPMI (HCT 8, HCT 116) (Gibco, Thermo Fischer Scientific 
(Waltham, MA, US)) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 
and 100 μg/ml streptomycin at 37°C with 5% CO2 and 95% humidity. The multiplicity of infection 
was approximately 1. 
3.2.5 Determination of dye uptake with flow cytometry 
Uptake measurement were carried out as described in Chapter II, using the uptake buffer (125 mM 
NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 12 mM MgSO4, 25 mM MES, and 5.6 mM 
glucose, with the pH adjusted to 8.5, 7.4, 6.5, 5.5 or 4.5 using 10 N NaOH or 1 M HEPES) in a final 
volume of 100 µl. The exact concentrations and incubation times are indicated in the Figure legends. 
Viability dyes were reconstituted with DMSO following the manufacturers’ protocols. The reaction 
was stopped by adding 1 ml ice-cold phosphate-buffered saline (PBS). The cells were kept on ice until 
flow cytometry analysis. The fluorescence of min. 20,000 live cells were measured using an Attune 
Acoustic Focusing Cytometer (Applied Biosystems, Life Technologies, Carlsbad, CA, US). Dead cells 
were excluded by propidium iodide (PI, 1 µg/ml) positivity. Functional data represents the mean of 
at least 3 independent experiments done on different days. In the case of A431 cells, cells were 
collected after trypsinization (0.1% trypsin) and the uptake experiments were performed in the same 
way as described for insect cells (Chapter II). Histogram figures were generated by the FCS Express 
software. 
3.2.6 96-well microplate-based assay.  
OATP-expressing A431 cells were plated (6 × 104 cells in 200 µl final volume/well) onto 96-well plates 
and grown for 16–24 h at 37°C, 5% CO2. The supernatant was removed the following day and the 
cells were washed 3-times with 200 µl of PBS. When we used inhibitors, the cells were pre-incubated 
with the inhibitors (dissolved in DMSO) for 5 min at 37°C (usually in 50 µl volume). The amount of 
DMSO was kept below 0.5% throughout the study. Side note: this amount of the solvent did not 
influence the fluorescence of the dyes. The reaction was started with the addition of 50 µl fluorescent 
dye (1–40 µM final concentration or 0.05 µl–1.2 µl in a final volume of 100 µl) and the plate was 
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incubated at 37°C for 2–30 minutes. The reaction was stopped by adding 200 µl ice-cold PBS. The 
supernatant was immediately removed, and then, the cells were washed 3-times with 200 µl ice-cold 
PBS. Lastly, 200 µl PBS was added to the cells and fluorescence was measured at room temperature 
using an Enspire fluorescent plate reader (Perkin Elmer) at wavelengths indicated in Table 3.1. 
3.2.7 Cell sorting 
Cells were sorted based on Live/Dead Green (LDG) positivity (this dye labels dead cells and cells 
when it gets taken up by OATP-mediated transport). Briefly, cells expressing OATP1B1, OATP1B3 
or OATP2B1 (2–4 × 106 cells/sample) were incubated with 0.8–1.2 µl LDG in 100 µl uptake buffer 
(sterile filtered), pH 5.5 at 37°C for 30 minutes. Cells were washed with 1 ml DMEM and centrifuged 
at 300 g for 4 minutes. After removing the supernatant, cells were resuspended in 500 µl DMEM. 
Cellular fluorescence was measured using a BD FACSAria III Cell sorter (BD Biosciences, San Jose, 
CA, US). Cells with the highest fluorescence (see the applied gate (“LDG+”) on Figure 3.1) were 
sorted for further analysis. Cells kept in culture for maximum 20 passages were used for the 
experiments. 
3.2.8 Western blot 
Whole-cell lysates of Sf9 or A431 cells (10–50 µg) were separated on 7.5% Laemmli SDS-PAGE gels. 
Protein transfer to PVDF was performed using the Bio-Rad miniProtean 3 system. Protein 
concentrations were determined using the Lowry method using BSA as standard. PNGase F (New 
England BioLabs) digestions were carried out following the manufacturer’s protocol. Membranes 
were incubated overnight with polyclonal antibodies. The antibodies used for the detection of 
OATP1B1 and OATP2B1 were kind gifts from Dr. Bruno Stieger (Department of Clinical 
Pharmacology and Toxicology, University Hospital, 8091 Zurich, Switzerland) 139. Other antibodies 
were anti-β-actin (A1978, Sigma) and anti-OATP1B3 (AMAb9123, Atlas Antibodies, Stockholm, 
Sweeden). After O/N incubation, PVDF membranes were incubated with 10,000–20,000x diluted 
HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (Jackson ImmunoResearch, Suffolk, 
UK) for 1h. Luminescence was detected using the Luminor Enhancer Solution kit by Thermo 
Scientific (Waltham, MA, US). 
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3.2.9 Immunofluorescent staining and confocal images 
Cells (2 x 105) were seeded onto 8 well µ-Slide (Ibidi, 80826) and cultured for 16-24 h at 37oC, 5% 
CO2. Cells were washed twice with 300 µl PBS and fixed with 100 µl 4%PFA-PBS for 15 min and 
washed three times with 300 µl PBS. Cells were blocked in PBS supplemented with 0.5% BSA, 0.5 % 
fish gelatin, 0.1% Triton-X and 5 % goat serum for 1 h at RT. Then, the primary antibody was added, 
and cells were incubated at 4°C O/N. The slides were washed with PBS 3 times the following morning 
and incubated with the secondary antibody for 1h at RT. On the end, the slides were washed 4 times 
with PBS and kept in PBS+ 0.1% sodium-azide solution until microscopy. Fluorescence was imaged 
by Zeiss LSM 710 confocal microscope with 40x oil immersed objective. Images were captured and 
analyzed by Zen 2 (Blue edition) Software. 
3.2.10 Toxicity testing 
5 × 103 A431 cells were seeded onto 96-well plates in a final volume of 100 µl DMEM. The following 
day, the cells were washed with PBS and 0.4 or 1.6 µl Live/Dead Green or Zombie Violet was added/5 
× 105 cells in a 100 µl final volume of uptake buffer. After 30 min of incubation, the cells were washed 
twice with PBS, and 200 µl DMEM was added to the cells. 144 hours later, the viability of the cells 
was determined with PrestoBlue (Thermo Fischer Scientific) assay. Briefly, the medium was removed, 
and cells were incubated for 60 mins at 37°C in 100 µl 5% PrestoBlue in PBS. Absorbance was 
detected at 583 nm with an Enspire fluorimeter (Perkin Elmer). Cells incubated with the uptake buffer 
alone served as control. Background signal was calculated by absorbance measured in empty wells 
filled with 5% PrestoBlue. 
3.2.11 Data analysis and statistics 
Z-factor was calculated as follows: 1−((3×SDnegative control 3×SDpositive control)/(Meanpositive−Meannegative)) 
based on Zhang et al. 201. Kinetic parameters of dye uptake or inhibition were analyzed by Hill fit curve 
fitting using the GraphPad Prism 8 software. Statistical significance was calculated by Student’s t-test. 
The p value for statistical significance was set at 0.05 (*), 0.01 (**) or 0.001 (***). 
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3.3 Results part I-Assay development 
3.3.1 Zombie Violet is a novel substrate for human OATP1B1, 
OATP1B3 and OATP2B1 
As our aim was to find better fluorescent substrates for the hepatic OATPs, we reviewed the literature 
in search for dyes with low membrane permeability and pH independent fluorescence. Viability dyes 
seemed to fit these characteristics, as they show low membrane permeability. Furthermore, 
repurposing commercially available viability dyes for studying transporter function was shown before; 
as Calcein, an acetoxymethyl ester (AM) derivative has been used extensively to study P-glycoprotein 
(ABCB1) and MRP (ABCC) function 192. As described in Chapter II, we have developed an insect 
cell-based assay to measure OATP-transporter activity. Therefore, we used this system to screen 
potential substrate candidates. Measuring the cellular uptake of an amine-reactive fluorescent viability 
dye, Zombie Violet (ZV) in OATP1B1 expressing cells turned out to be our first promising hit. To 
distinguish staining between dead cells and transporter-mediated dye uptake, we counterstained the 
cells with propidium-iodide (PI). Comparing control cells to OATP1B1 expressing cells, we observed 
marked differences in the stained cell populations. While control cells stained with ZV were always 
accompanied by PI positivity, OATP1B1 expressing cells showed two separate subpopulations: one 
ZV positive and PI negative and one double-positive indicating that ZV can penetrate the cells via 
OATP-mediated uptake (see Figure 3.1). Further measurements confirmed that ZV uptake is 
mediated by OATP1B1 function, and the transport showed saturable and inhibitor-sensitive uptake 
(Figure 3.2). It needs to be noted here, that the chemical structure of the viability dyes, including ZV 
could not be obtained from the supplier, hence Km values for the viability dyes cannot be determined. 
 
Figure 3.1 ZV uptake in Sf9 cells. 0.2 µl dye in 100 µl uptake buffer was measured at 37°C in pH 5.5 uptake 
buffer for 15 min. Dead cells were identified by PI positivity. One representative experiment is shown.  
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Figure 3.2 Upper panel: Time-dependent ZV uptake in Sf9 cells expressing OATP1B1. Uptake rates 
were normalized to the fluorescence values measured for OATP1B1 (minus the fluorescence in control cells) 
incubated with 2 µl ZV for 30 min. Lower panel: OATP1B1-mediated transport inhibited by cholic acid 
(a known inhibitor of OATP1B1 function). Intracellular accumulation of 0.1 µl ZV/ 5x105 cells in 100 µl was 
measured with increasing concentrations of cholic acid (0.1–100 µM) for 20 min. Data show the means ± SD 
of 3 independent experiments. Sf9 cells overexpressing an unrelated protein were used as control (see Chapter 
II-Methods). 
In the next set of experiments, we tested whether any other human OATP would show transporter-
mediated ZV uptake. We found that OATP1B3 and OATP2B1 expressing Sf9 cells were also able to 
mediate ZV uptake, although to a lesser degree (Figure 3.3). Since the expression levels of the 
different human OATPs cannot be compared in the lack of a pan anti-OATP antibody, it cannot be 
defined whether these differences in the transport rate are due to different expression levels or due to 
differences in the affinity toward ZV. 
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Figure 3.3 Zombie Violet (ZV) uptake measured in Sf9 cells expressing human OATPs. Cells were 
incubated with 0.2 µl/100 µl uptake buffer adjusted to pH 5.5 for 30 min at 37°C. Control cells (ctr.) were 
expressing an unrelated protein 136. Average of at least three independent measurements with duplicates ±SD 
values are shown. Student t-test were used to determine significance, *p< 0.05  
As OATP1B1, OATP1B3 and OATP2B1 were able to transport Zombie Violet in our preliminary 
screens we further characterized the uptake. The transport in these cells was sensitive to the pH- 
Figure 3.4). The highest OATP-mediated transport rate was observed at pH 5.5 for all three 
transporters which we were able to inhibit with previously described OATP-interacting compounds 
(Figure 3.5). Furthermore, OATP1B1 and OATP1B3 demonstrated transport at pH 7.4, while 
OATP2B1 stayed inactive at neutral pH. No transport could be observed at pH 8.5. These 
experiments demonstrated that Zombie Violet is a bona fide OATP1B1, OATP1B3 and OATP2B1 
substrate.  
 
Figure 3.4 pH dependent ZV uptake in Sf9 cells. Cells were incubated with 0.2 µl ZV/5x105 cells uptake 
buffer adjusted to pH 5.5 for 10 min at 37°C. Control cells (ctr.) were expressing an unrelated protein 136. Bars 
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represent the average of three independent experiments ±SD values. Significance: p <0.05 (*), p < 0.01 (**) 
or p<0.001 (***). 
Besides, we also tested two other fixable amine-reactive viability dyes, Zombie Green (ZG, Bio 
Legend) and Live/Dead Green (LDG, Life Technologies). Although ZG was not transported by 
OATPs, we found that LDG was a substrate of OATP1B1, OATP1B3 and OATP2B1 (Figure 3.6).  
 
Figure 3.5 Inhibition of ZV uptake in Sf9 cells expressing OATP1B1, OATP1B3 or OATP2B1. Uptake 
of 0.2 µl ZV/5x105 cell was measured in the absence or presence of the following compounds after 30 min 
incubation in uptake buffer pH 5.5 at 37°C: 20 µM cyclosporin A (CsA), 150 µM cholic acid (CA), 150 µM 
glycocholic acid (GC), 150 µM taurocholate (TC), 50 µM estradiol 17-β-D-glucuronide (EG), 10 µM 
methotrexate (MTX), 50 µM imatinib, 20 µM ursolic acid (UA), 5 µM prostaglandin E2 (PGE2). Fluorescence 
measured in control cells (ctr.) expressing an unrelated protein 136 were subtracted. Transport measured in cells 
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with ZV alone was set 100% and the effect of the compounds was compared to this value. Bars represent the 
average of three independent experiments ±SD values. Significantly different from the control: *p < 0.05, **p 
< 0.01. 
Figure 3.6 ZV and LDG uptake in 
Sf9 cells expressing OATP1B1, 
OATP1B3 or OATP2B1. Dye 
uptake was measured after 30 mins 
of incubation at pH 5.5, 37°C (0.2 µl 
dye/ 5x105 cells). Data points 
represent the average of at least three 
independent measurements ±SD 
values. Cells expressing an unrelated 
protein were used as control. 
Significance: p <0.05 (*), p < 0.01 
(**) or p<0.001 (***). 
 
3.3.2 Establishment of a novel viability dye-based cell sorting method 
to create cell lines with high OATP1B1, OATP1B3 and OATP2B1 
expression 
Although the baculovirus insect cell system proved to be an excellent tool for initial substrate screens, 
the transient nature of its protein expression is not compatible with high-throughput screening 
methods (HTS). As our primary goal with this project was to build a robust screening platform to 
study OATP drug interactions, human-derived cell lines with stable expression of OATP1B1, 
OATP1B3 or OATP2B1 were required to adapt our transport measurements for a 96-well plate-based 
setup. We choose A431 cells (human epidermoid carcinoma) because of its strong adherence. Our 
first attempt to overexpress hepatic OATPs in this cell line resulted in a well-detectable OATP2B1 
overexpression. However, regardless of repeated lentiviral transduction, we could only detect low 
OATP1B1 and OATP1B3 protein levels. If we compared the protein levels between Sf9 cells and 
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Figure 3.7 Low level of OATP1B expression in A431 cells demonstrated by Western blot. Controls (ctr.) 
represent either Sf9 cells expressing an unrelated protein or mock-transfected A431 cells. Whole-cell lysates 
were separated on 7.5% Laemmli SDS-PAGE. Different migratory bands most probably represent different 
glycosylated forms of OATPs.  
Subsequently, Fl-MTX (a common hepatic OATP substrate, see more in Chapter II) uptake in these 
cells was low. Additionally, we could only measure convincing Fl-MTX, ZV and LDG uptake in 
OATP2B1 overexpressing A431 cells (Figure 3.8a). Transduction with viral vectors usually results in 
a high degree of target protein expressing cells, however the transduction efficiency is never 100%. 
Additionally, the substrate uptake should be proportional to protein expression and function. Thus, 
we were interested to see if we could identify the subpopulations of cells with elevated OATP 
expression based on increased substrate accumulation. As LDG didn't seem to be toxic (data not 
shown here but present in the publication142), we sorted cells with the highest LDG signal transduced 
with OATP1B1, OATP1B3 or OATP2B1. This also included dead cells as they had high LDG signal, 
but as these cells were dead, they have washed away after the first passage. Sorted cells were then 
further maintained and grown. These cell populations showed significantly higher OATP expression 
and improved function compared to the unsorted cells (Figure 3.8b and Figure 3.9). The expression 
levels were stable for at least 2 months, about 20 passages. Our results strongly suggest that OATP 
function-based sorting is possible with LDG. This method could be a new tool for the selective 
enrichment of OATP proteins in different cell lines. 
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Figure 3.8 Fluorescent substrate uptake in A431 cells. Uptake of 1 µM fluorescein-methotrexate (Fl-MTX), 
0.4 µl Live/Dead Green (LDG) or Zombie Violet (ZV)/ 5x105 cells were measured before (a) and after (b) 
sorting of LDG positive cells. Mock transfected cells were used as controls (indicated by filled histograms). 
Cells were incubated for 15 min (Fl-MTX) or 30 min (LDG and ZV) at 37°C in pH 5.5 uptake buffer. Dead 
cells were excluded based on PI staining. This experiment was repeated several times, histograms show the 
results of one representative experiment. 
 
Figure 3.9 Sorting with LDG results in increased OATP protein expression. Controls (ctr.) represents 
mock transfected A431 cells and β-actin serves as an internal control. Whole cell lysates (20 µg each) were 
separated on 7.5% Laemmli SDS-PAGE. One representative blot is shown. Multiple bands probably represent 
diverse glycosylation levels of these proteins.  
 
Page | 65  
 
To further demonstrate that our novel method is suitable for OATP function-based sorting, we sorted 
freshly transduced HEK-293T and MDCKII cell lines. After recovery, the cells were cultured and 
tested for transporter-mediated substrate accumulation. Ultimately, we obtained cell lines expressing 
OATP1B1, OATP1B3 or OATP2B1 with measurable transporter activity (Figure 3.10). See more 
examples of the successful application of this sorting strategy later in this chapter. 
 
Figure 3.10 Zombie Violet (ZV) uptake in HEK-293 and MDCKII cells expressing OATPs, 1B1, 1B3 
or 2B1. Intracellular accumulation of 0.1 μl ZV / 5x105 cells in 100 μl was measured at pH 5.5 for 30 min. 
Dead cells were excluded based on PI staining (1 μg/ml). Experiments were repeated at least two times. One 
representative experiment is shown. Filled histograms show fluorescence measured in cells transfected with the 
empty vector. 
 
3.3.3 A semi-high throughput assay for OATP-drug interaction 
screens 
3.3.3.1 Other commercially available fluorescent substrates for the hepatic 
OATPs 
Our initial hits were from a family of amine-reactive dyes used for live/dead cell discrimination. There 
are quite a few more commercially available dyes designed for the same purpose. Additionally, we also 
found other cell impermeant dyes, such as Cascade Blue hydrazide (CB) and Alexa Fluor 405 
succinimidyl ester (AF405). Both of these compounds are used in cell permeability assays and for 
protein labeling 202. Thus, we put together a panel of possible substrates and tested whether they show 
OATP-mediated cellular accumulation (See Table 3.1 for the tested compounds). We plated the cells 
on a 96-well plate and tested our candidates under the same conditions used in our flow cytometric 
experiments. 




Bio Legend Zombie Green ZG 488/515 
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Live/Dead Blue LDB 350/450 
Live/Dead Aqua LDA 267/526 
Live/Dead Violet LDV 416/451 
Live/Dead Yellow LDY 400/475 
Live/Dead Green LDG 495/520 
Live/Dead Red LDR 595/615 
Live/Dead Far-red LDFR 650/665 
Live/Dead near-IR LDNIR 750/775 
Alexa Fluor 405 NHS ester AF405 401/421 
Cascade Blue hydrazide CB 400/419 
Table 3.1 Fluorescent dyes used in the current study to screen for novel fluorescent OATP substrates. 
All dyes were tested in A431 cells expressing OATP1B1, OATP1B3 and OATP2B1.  
 
Our results showed transporter-mediated uptake of some of these dyes. Moreover, ZV, LDG, CB and 
AF405 surpassed Fl-MTX signal intensity (see later on Figure 3.12 and Table 3.2), indicating that 
these dyes are a better fit for fluorescence-based OATP-studies. (Alas, the other compounds listed in 
Table 3.1 were not transported by the investigated OATPs.) 
3.3.3.2 A microplate-based functional assay 
With the aim of optimizing the protocol and to find the ultimate dye for semi high-throughput uptake 
measurements we characterized the uptake of the new OATP1B and OATP2B1 substrates. We 
measured the transport of our newly identified substrates in A431 cell expressing OATP1B1, 
OATP1B3 and OATP2B1 seeded in 96-multiwell plates (Figure 3.11).  
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Figure 3.11 Additional hepatic OATP substrates. Transport was measured in A431 cells overexpressing 
OATP1B1, OATP1B3 and OATP2B1. Cells were seeded onto 96-well plates. 1 µl ZV, LDV, LDG, 1 µM (or 
4 µM for OATP2B1) Fl-MTX or 20 µM CB and AF405 for 30 minutes at 37 °C in buffer with pH 5.5, in final 
reaction volume of 100 µl. Fluorescence was determined using a fluorescent plate reader. The activity was 
calculated by dividing fluorescence measured in A431-OATP cells with that measured in A431 mock-
transfected cells. Average of at least three independent measurements with triplicates ± SD values are shown. 
As we optimized the assay conditions, the highest transport ratios for OATP1B1 and OATP2B1 were 
observed at pH 5.5. Figure 3.12 shows the pH-dependent ZV, CB and AF405 uptake in A431 cells 
(LDG is not shown here).  
Our results show a rapid uptake of these compounds with a strong and stable signal. Opposed to Na-
fluo and Fl-MTX, amine-reactive dyes stably bind to proteins upon entry into the cytoplasm. The cells 
retained a robust signal for more than 60 minutes without significant loss of the fluorescence intensity. 
Sadly, patent protects the commercially available viability dyes, thus the chemical structures and dye 
concentrations are not available. However, Alexa Fluor 405 NHS ester: (Tris(N,N-
diethylethanaminium)8-[2-(4-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl)-2-
oxoethoxy]pyrene-1,3,6-trisulfonate) and Cascade Blue hydrazide: ([(3,6,8-trisulfo-1-pyrenyl)oxy]-
,1-hydrazide) are well documented dyes. Consequently, we choose to continue characterizing these 
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Figure 3.12 pH-dependent dye uptake in A431 cells. Transport was measured in 96-multiwell plates 
containing 1.2 x 105 cells/well. Cells were incubated with the dyes for 30 minutes in uptake buffer pH 5.5, 6.5 
or 7.4. Dyes were added as follows: A431-OATP1B1 0.2μl/100 μl ZV, 2 μM CB and 1 μM AF405; A431-
OATP1B3 0.2 μl/100 μl ZV, 20 μM CB and 5 μM AF405; A431-OATP2B1 0.2 μl/100 μl ZV, 5 μM CB and 
2.5 μM AF405. Experiments were performed in triplicates with three parallels in each biological replicate. 
Average ± SD values are shown. 
As seen on Figure 3.13, Fl-MTX uptake was similar for OATP1B1 and OATP1B3, while OATP2B1 
has a lower affinity for this compound. Even though Fl-MTX was shown to be higher affinity 
substrate opposed to CB and AF405, the Vmax of Cascade Blue transport for OATP1B1 and 
OATP2B1 was 2-3-fold higher, as their transport significantly exceeded that of Fl-MTX. Although 
OATP1B3 is also able to transport CB, the best substrate for OATP1B3 seems to be Alexa Fluor 405 
as the Vmax is 3-fold-higher compared to Fl-MTX. The important note here that the expression levels 
of the three OATPs cannot be directly compared, as there isn’t any antibody that recognizes all three 
proteins. Therefore, the maximum uptake rates cannot be directly compared. 
After optimizing the assay conditions, we measured OATP-mediated uptake for each dye. In 
summary, ZV showed the highest fluorescent signal (OATP vs. mock transfected control) for all three 
OATPs. CB proved to be an equally good substrate for OATP1B1 and OATP2B1 as ZV. The 
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Figure 3.13 Concentration-dependent uptake kinetics of fluorescein-methotrexate (Fl-MTX), Cascade 
Blue and Alexa Fluor 405 (Alexa 405) measured in A431 cells expressing OATP1B1, OATP1B3 or 
OATP2B1. Transport was assessed in 96-well plates in the linear phase of uptake (2.5 minutes for Fl-MTX, 10 
minutes (1B1, 2B1) or 15 minutes (1B3) for Cascade Blue, and 15 minutes for Alexa 405). Transport capacity 
was calculated based on calibration with known amounts of the dyes. Data points represent the average 
transport rates after background subtraction (measured in mock-transfected cells) from three independent 
measurements ±SD values. 
Page | 70  
 
 
Table 3.2 A431 cells (seeded in 96-well plates) were incubated with the dyes at pH 5.5 for 30 minutes 
in order to reach the maximum fluorescent signal. Data were calculated from at least 3 independent 
measurements. Dyes were applied in the following concentrations/amounts: Fl-MTX 1 µM (OATP1B1 and 
1B3) and 4 µM (OATP2B1); ZV, LDV and LDG 1-1 µl; CB and AF405 10 µM (OATP1B1 and 2B1) and 20 
µM (OATP1B3). A z-factor above 0.5 is considered to be an excellent assay 201. Numbers in bold indicate dyes 
meeting these criteria. Dyes defined as best candidates for HTS are indicated in bold. 
3.3.3.3 Inhibition assay for OATP-drug interaction screening using Cascade 
Blue and Alexa Fluor 405 
After finding the ideal dyes and optimal assay conditions (incubation time, pH and dye dilutions), we 
tested the applicability of the assay for the detection of OATP-drug interactions using known 
OATP1B and OATP2B1 interacting compounds. Our results showed that the transport of Cascade 
Blue and Alexa Fluor 405 was inhibitor sensitive (Figure 3.14). 
1B1 1B3 2B1 1B1 1B3 2B1
Fl-MTX 2.14 ±  0.44 2.49 ±  0.72 1.24 ±  0.16 0.59 0.77 -1.8
Zombie Violet 11.05 ±  2.47 6.03 ±  1.43 14.65 ±  2.47 0.61 0.61 0.71
Live/ Dead 
Violet
2.03 ±  0.59 1.33 ±  0.21 3.50 ±  0.53 0.55 -0.42 0.79
Live/ Dead 
Green
3.82 ±  0.51 6.58 ±  1.73 6.74 ±  2.82 0.84 0.76 0.62
Cascade Blue 10.79 ±  2.46 1.71 ±  0.16 7.31 ±  2.17 0.73 0.26 0.66
Alexa Fluor 
405
5.32 ±  1.22 4.65 ±  0.51 5.46 ±  2.46 0.59 0.64 0.57
Transport ratio compared to control z-factor
Page | 71  
 
 
Figure 3.14 Inhibition of 10 µM Cascade Blue or 5 µM Alexa Fluor 405 uptake in A431 cells expressing 
OATP1B1, OATP1B3 and OATP2B1.Fluorescence was measured after 30 min incubation at 37°C, pH 5.5. 
Uptake was inhibited with the following compounds: 150 µM cholic acid (CA), 150 µM glycocholic acid (GC), 
150 µM taurocholate (TC), 50 µM estradiol 17-β-D-glucuronide (EG), 20 µM cyclosporin A(CsA), 100 µM 
bromsulphthalein (BSP). Transport measured in cells with the dye alone was set 100% and the effect of the 
compounds was compared to this value. Bars represent the average of at least three independent experiments 
±SD values. 
 
Furthermore, we measured the concentration-dependent inhibition kinetics for cyclosporin A (CsA) 
and estrone-3-sulfate (ES) (Figure 3.15). CsA is a well-known inhibitor 112,203 and estrone-3-sulfate is 
a substrate for hepatic OATPs 43,193. The measured IC50 values obtained in the novel fluorescence assay 
were comparable to the ones using radiolabeled substrates (Table 3.3). Z-factor is used to determine 
the robustness of a HTS assay 201. Here we found that almost all the assays show a z-factor above 0.5 
(summarized in Table 3.2), indicating that they are suitable for HTS OATP-drug interaction screens. 
 OATP1B1 OATP1B3 OATP2B1 
 our data literature our data literature our data literature 
CsA 0.07± 0.04 
0.1 133,143, 0.2 204, 1.3 
205 
0.18±0.05 
0.2 204, 1.2 
205 
1.45±0.11 36 205 
E1S 0.22±0.004 0.05133,204 9.5±0.13 20 204 0.56±0.05 no data 
Table 3.3 Comparing IC50 values between our and literature data. IC50 (µM) values were obtained using 2 
or 10 µM CB (OATP1B1 or OATP2B1) or 5 µM AF405 (OATP1B3). Literature data shows IC50 values 
obtained in assays using estradiol-17--D-glucuronide, estrone-3-sulfate, 8-fluorescein-cAMP or 
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Figure 3.15 Inhibition of OATP-mediated Cascade Blue (CB) and Alexa Fluor 405 (AF405) uptake in 
A431 cells. 2 µM CB for OATP1B1, 10 µM CB for OATP2B1 and 5 µM AF405 for OATP1B3. Transport was 
measured after 30 min incubation in uptake buffer, pH 5.5 at 37°C. Data represents transport activity corrected 
with background fluorescence measured in mock transfected cells. Figures show the average of three 
independent measurements performed with three parallels ±SD values.  
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3.4 Results part II-Assay applications 
 3.4.1 The use of Cascade Blue to confirm new OATP2B1 interactions 
(These results were published in Windt et al, Archives of Toxicology, 2019 206) 
The A431-OATP2B1 cell line established in my work has already been utilized for OATP2B1 related 
functional studies. In this particular study, we screened drugs that might contribute in OATP2B1-
mediated toxicity. Although several chemotherapeutics have already been identified as OATP2B1 
substrates, the OATP2B1-mediated sensitization of the cells toward cytostatics has not yet been 
demonstrated. By screening the toxicity of 101 FDA approved drugs our group investigated the 
influence of key drug-transporters, including OATP2B1 on the toxicity of approved anticancer drugs. 
In these experiments performed by my colleagues, several chemotherapeutic compounds were 
identified causing increased toxicity in OATP2B1 expressing cells. This toxicity can be explained by 
increased anticancer drug uptake by OATP2B1. In order to verify these new interactions, we used our 
Cascade Blue based assay and measured CB uptake in the presence of these compounds. If a drug 
alters CB uptake (both inhibition and activation can be expected) it proves the interaction with 
OATP2B1. As shown in Figure 3.16 and Table 3.4 the putative OATP2B1 substrates identified by 
the cytotoxicity screen inhibited CB uptake.  
NSC number Compound IC50 values 
NSC-125066 Bleomycin 64.15±6.1 
NSC-712807 Capecitabine 124.01±6.42 
NSC-628503 Docetaxel 11.32±0.38 
NSC-616348 Irinotecan 17.03±1.46 
NSC-180973 Tamoxifen 10.99±0.7 
NSC-740 Methotrexate 265.50±31.38 
NSC-122819 Teniposide 4.59±0.4 
NSC-141540 Etoposide 1.88±0.32 
NSC-6396 Thioplex 574.28±282.7 
Table 3.4 Inhibition of OATP2B1-mediated Cascade Blue (CB) uptake by the putative OATP2B1 
substrates identified in the cytotoxicity screen. Transport was measured as indicated under Figure 3.15. 
Experiments were performed in triplicates with three parallels in each biological replicate. Average ± SD values 
of IC50 values are shown 




Figure 3.16 Inhibition of OATP2B1-mediated Cascade Blue (CB) uptake by the putative OATP2B1 
substrates identified in the cytotoxicity screen. Transport of CB (10 µM) was measured for 30 min in 
increasing concentrations of the investigated compounds on 96-well plates. IC50 values were determined by 
measuring the intracellular accumulation of Cascade Blue in the presence of increasing concentrations of 
OATP2B1 interacting compounds. Experiments were performed in triplicates with three parallels in each 
biological replicate. Average ± SD values of IC50 values are shown. 
 
3.4.2 The cancer specific isoform of OATP1B3-Where do we stand? 
(The data presented here have not been published yet) 
As it was mentioned in Chapter I, ectopic expression of OATP1B3 has been shown in multiple types 
of cancer 4,71. Moreover, a number of studies have proved the existence of two cancer specific 
OATP1B3 variants, OATP1B3 CT and OATP1B3 V1 72,73. These isoforms seem to utilize alternative 
transcription initiation sites; therefore, the translated protein products lack the first 28 (OATP1B3 
V1) or 47 (OATP1B3 CT) amino acids at the N-terminus of the canonical OATP1B3. Topology 
modeling predicts a transporter-like structure for both versions. While OATP1B3 V1 is predicted to 
have 12 transmembrane helices, which are the typical structure of OATPs, the CT isoform has only 
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10 TM helices indicating that this variant may not be functional (Figure 3.17). Studies have agreed 
that CT is localized intracellularly, and it might be functionally inactive.  
 
Figure 3.17 Predicted membrane topologies of the OATP1B3 isoforms. Topology was determined by 
CCTOP (Dobson et al. 207), image was drawn by using the Protter program 
(http://wlab.ethz.ch/protter/start/). 
 
However, there are discrepancies in the literature about the localization and function of OATP1B3 
V1. Imai et al., showed that OATP1B3 V1 is localized to the plasma membrane with measurable 
transporter-mediated fluvastatin and rifampicin uptake 74, whereas Thakkar et al., and Chun et al. 
described no or very low level of transporter function and reduced plasma membrane localization 73,208. 
Furthermore, Chun et al. was also showing that the first 50 amino acids are crucial for the plasma 
membrane localization of OATP1B3 208. 
Therefore, our goal here was to express these two isoforms of OATP1B3, CT and V1 in different cell 
lines and see whether they are localized to the plasma membrane and have any measurable transporter 
activity. A431 cell lines were previously shown as an ideal cell model for OATP expression related 
functional studies (Patik et al., and Windt et al. 142,206), Therefore, we choose A431 cell as our reference 
point; and we also transduced colorectal carcinoma-derived cell lines where previous papers have been 
able to detect endogenous OATP1B3 expression by RT-PCR 71. 
3.4.2.1 Cell lines expressing OATP1B3 isoforms 
First, we transduced A431, HCT 8 (ileocecal colorectal adenocarcinoma) and HCT 116 (colorectal 
carcinoma) cell lines cells with the different OATP1B3 isoforms. Generating the cell lines with marked 
protein expression appeared to be challenging. Following our previous observations with OATP1B1 
and OATP1B3 (wild type, Chapter III, 3.3.2), the cells did not tolerate forced OATP expression. 
Nevertheless, we tried to sort the cells using the truncated CD4 receptor encoded in our transfection 
vector (see Methods, Chapter III, 3.2.2), but we could only attain minor protein enrichment. Although 
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the available data are inconsistent with the function of the OATP1B3 V1 isoform, we tried to sort 
these CD4-presorted cells based on LDG positivity (described in Chapter III). This method proved 
to be useful again in the case of OATP1B3 WT and V1, as after four rounds of cell sorting, we got 
cells with detectable protein expression. However, in the case of OATP1B3 CT we did not detect any 
LDG positivity, therefore we applied repeated CD4-fragment based-sorting (data not shown). When 
we tested transporter function in these cell lines, we could detect increased OATP-mediated uptake 
of the well-documented substrate Fl-MTX in the LDG sorted OATP1B3 WT and OATP1B3 V1 cell 
lines, but only low transport in the CD4 sorted cells (Figure 3.18 shows the results from HCT 8 cell 
lines). Furthermore, our results show that OATP1B3 V1 is a functional isoform. Although we did not 
detect OATP1B3 CT mediated Fl-MTX uptake, which could imply either a non-functional protein or 
lack of protein expression. Therefore, we had to examine whether this protein is present in these cell 
lines as CD4 expression does not necessarily correlate with OATP1B3 expression (See the results later 
in the text). 
 
Figure 3.18 Fl-MTX uptake in HCT-8 cells expressing OATP1B3 WT, OATP1B3 V1 or OATP1B3 CT 
after sorting based on CD4 expression and/or LDG uptake. Cells were incubated with 1 µM Fl-MTX for 
15 min at pH 5.5, 37°C. Fluorescence was detected by flow cytometry. Dead cells were excluded based on PI 
staining. Ctr: mock-transfected cells, CD4: cells were sorted based on labeling with the anti-CD4 antibody 
(Sigma) and anti-mouse Alexa-488 secondary antibody, LDG: cells sorted based on LDG positivity (see 
Chapter III, 3.2.7). Experiments were repeated three times, one representative experiment is shown. 
 
3.4.2.2 Cellular localization of cancer-specific OATP1B3 isoforms 
Visual examination of OATP1B3 expression by confocal microscopy revealed mainly plasma 
membrane localization for OATP1B3 WT and OATP1B3 V1. However, OATP1B3 CT showed 
mostly cytoplasmic localization in A431 (not shown) and HCT 8 cells (Figure 3.19) and very low 
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expression in HCT 116 cells (Figure 3.20). Low expression levels might be explained by improper 
folding and decreased protein stability of OATP1B3 CT. 
 
Figure 3.19 OATP1B3 expression in HCT 8 cells. Cells were labeled with an anti-OATP1B3 antibody (Atlas 
antibodies, 1:500 dilution) and Alexa-488-conjugate anti-rabbit secondary antibody (Sigma, 1: 250 dilution). 
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Figure 3.20 OATP1B3 expression in HCT 116 cells. The same antibodies were used as described above for 
HCT 8 cells. 
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Most cell-surface membrane proteins are glycosylated on their extracellular domains. Therefore, we 
assessed the glycosylation status of OATP1B3 WT and V1 after removing the N-linked 
oligosaccharides by PNGase F digestion. Western blot analysis of whole-cell lysates with and without 
PNGase treatment showed marked shifts in the molecular weight of OATP1B3 WT and OATPP1B3 
V1 (Figure 3.21). As OATP1B3 CT only showed cytoplasmic localization, we excluded those samples 
here.  
 
Figure 3.21 Western blot analysis of over-expressed OATP1B3 WT, OATP1B3 V1 in different cell lines. 
Whole-cell lysates with (+) or without (-) PNGase F treatment. 1:2000 anti-OATP1B3 antibody (Abcam), 
1:20000 anti-mouse HRP. Total protein amounts: A431: 1 µg in VC (vector control), WT and V1, HCT 116: 
10 µg in VC and WT, 20 µg in V1, HCT 8: 10 µg in VC and WT, 20 µg in V1. Sf9 OATP1B3 WT: 0.05 µg 
Furthermore, using immunoblot analysis and confocal immunofluorescence microscopy, we 
demonstrated that OATP1B3 V1 expressed in A431, HCT 8 and HCT 116 cells show colocalization 
with E-cadherin in the plasma membrane. In Figure 3.22, expression of OATP1B3 V1 and E-
cadherin were examined by confocal microscopy. Red staining (first row) shows E-cadherin, green 
(second row) shows OATP1B3 expression and the third row shows merged images.  
Taken together, our preliminary results indicate that OATP1B3 V1 is localized to the plasma 
membrane and has a transporter function. In future studies, our laboratory would like to compare the 
function of OATP1B3 WT and V1 and test whether OATP1B3 V1 would result in increased 
sensitivity to chemotherapeutics. 
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Figure 3.22 Colocalization of E-cadherin and OATP1B1 in three different cell lines. Using red for E-
cadherin (on the left) and green fluorescent probes for OATP1B3 (middle row). When these images were 
merged, they showed a yellow signal, indicating that both proteins were colocalized (on the right). 1:1000 
mouse anti-OATP1B3 (Abcam) and 1:100 anti-pan-cadherin (PA5-16766 rabbit-Thermo Fisher) were probed 
with 1:250 mouse Alexa-488 and 1:250 rabbit Alexa 647 (Sigma) as secondary antibodies.  
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3.5 Discussion 
Hepatic OATPs are well-recognized players in transporter-mediated drug-drug interactions. The 
altered function of OATP1B1 and OATP1B3 due to mutations or drug-drug or food-drug interactions 
are directly implicated in the modification of drug pharmacokinetics and causing pharmacological 
toxicities 209 (e.g. bile acid congestion 100, statin-induced toxicity 50,210). In addition, OATP2B1 is an 
emerging candidate for contributing to these effects due to its possible role in SN-38 mediated 
gastrointestinal toxicity 211 or statin-induced myopathy 22. 
Moreover, OATPs are also recognized in cancer; not only as potential mediators of chemotherapy 
disposition but as potential future targets for cancer treatments or tumor markers 20. 
Taken together, these are the key reasons why OATPs receive increasing attention. The ITS recognizes 
OATP1A2, OATP1B1, OATP1B3, and OATP2B1 as main determinants of drug PK and 
recommends the investigation of these transporters during early drug development 83. The EMA also 
emphasizes the necessity to characterize specific transporter polymorphisms as they might alter drug 
absorption and efficacy 84. The pharmaceutical industry follows the recommendations as the common 
goal is to ensure drug safety, develop new therapies and prevent potential complications. To meet 
regulatory requirements, in vitro systems are required to estimate drug-transporter interactions. 
Radioactively labeled drugs have been an excellent choice to track a compound through the body and 
determine pharmacokinetics. 
Nevertheless, researchers are attempting to employ even better or newer techniques, such as mass 
spectroscopy (MS) to study ADME characteristics. Naturally, these techniques have limitations: they 
are costly and not applicable for larger compound screens. In order to increase the magnitude of these 
screens, new probes and more advanced assay technologies are required. Fluorescent tracers and 
compounds labeled with fluorescent tags are emerging as a cost-efficient substitution for radioligands. 
Also, fluorescent labeling promises higher flexibility in multicolor labeling. Several fluorescent 
OATP1B substrates have been identified in the past decade (e.g. Na-fluorescein and fluorescein-
methotrexate 132,212) and there were attempts to utilize these probes for semi-HTS or HTS formats 
55,131,196. However, due to sensitivity, stability and availability issues, these compounds are not ideal for 
larger compound screens 133. An increasing evidence suggests that OATP2B1 needs to be considered 
as a new target for pharmacokinetic studies 22,92,213–215. Interestingly, OATP2B1 has been reported to 
reach its highest transport activity under an acidic extracellular environment 1,136. However, fluorescent 
functional assay to study OATP2B1’s function on a larger scale has not been described.  
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Consequently, our goal was to develop experimental strategies to measure OATP-drug interactions 
with the help of fluorescent substrates. We bought commercially available fluorescent dyes with low 
cell-permeability, high quantum yield and pH independence. First, we choose to test amine-reactive 
viability dyes, and we identified Zombie Violet (ZV) and Live/Dead Green (LDG) as novel 
OATP1B1, OATP1B3 and OATP2B1 substrates (Figure 3.6). In the second set of experiments, we 
chose compounds (Cascade Blue Hydrazide and Alexa Fluor 405) from the same family but these are 
used to label proteins fluorescently.  
We have used our previously developed Sf9 cell-based assay to test our candidate substrates by flow 
cytometry. ZV showed transporter-mediated uptake in cells expressing OATP1B1, OATP1B3 and 
OATP2B1, but not in any other OATP member (Figure 3.3). The transport was recapitulated in 
A431 cells overexpressing the same proteins (Figure 3.8 and Figure 3.11). The other viability dye 
that we discovered as a new substrate for hepatic OATPs was LDG. As both dyes label dead cells and 
cells with high OATP1B1, OATP1B3 and OATP2B1 expression, a secondary dye is required to 
exclude cells with compromised membranes (Figure 3.1). Also, there are cell types with endogenous 
OATP expression (e.g. hepatocytes), calling for caution when these dyes are used for live/dead cell 
discrimination as subpopulations of live cells are excluded because of LDG positivity. However, 
currently, we have no data about the influence/relevance of endogenous levels of OATPs on the 
uptake of these dyes. 
For larger drug screens, we needed an adherent cell line with stable OATP expression. We generated 
A431 cells expressing OATP1B1, OATP1B3 and OATP2B1. Although this cell line has not been 
commonly used in pharmacological screens, it has been used before in microplate-based assay due to 
its strong adherence 216. Though our vectors contained a CD4 fragment as a selection marker, our 
primary attempts yielded cell lines (A431, MDCKII, HEK293T, HCT8) with very low expression 
levels of OATP (Figure 3.7 and Figure 3.18). Without any other existing selection marker, we 
attempted to sort cells based on OATP-mediated LDG uptake. This method helped to increase 
OATP1B and OATP2B1 protein expression levels which were accompanied by elevated transporter 
function in multiple cell lines (Figure 3.8-3.10 and Figure 3.18). According to our knowledge, using 
a fluorescent dye to enrich OATP-expression hasn’t been done before. This could be used as a new 
tool to generate cell lines with high OATP1B and OATP2B1 expression. Furthermore, without this 
novel sorting method, we would not have been able to demonstrate that the cancer-specific OATP1B3 
V1 has measurable transporter activity (Figure 3.18). With these cell lines, we could also demonstrate 
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plasma membrane localization for this protein in three different cell lines and made our contribution 
to the existing debate about these isoforms’ cellular localization (Figure 3.19-Figure 3.22). 
Our results measuring transporter activity in hepatic OATP expressing cell lines are consistent with 
previous studies showing enhanced OATP transporter activity under an acidic extracellular milieu 
1,40,42,211,217. In line with this, our newly identified OATP test substrates were almost exclusively 
transported at pH 6.5-5.5. Further studies are required to determine whether this enhancement is due 
to changes in the protonation levels in the transporter binding sites or in the substrates in an acidic 
environment. Nevertheless, the inhibition constants measured with this new assay are in full 
accordance with transport measurements carried out at neutral pH 133,204,205, indicating the usefulness 
of this system (Table 3.3).  
Although ZV, LDG and LDV are excellent substrates for hepatic OATPs, the exact transport kinetics 
could not be determined as the molecular structure is proprietary. Therefore, we could only provide 
detailed transport kinetics for the well-established hepatic OATP substrate; fluorescein-methotrexate 
and the two novel OATP1B1, OATP1B3 and OATP2B1 substrates; Cascade Blue, Alexa Fluor 405 
(Figure 3.12). OATPs had different affinities for different substrates. OATP1B1 and OATP2B1 
exhibited higher affinity for Cascade Blue, and OATP1B3 showed a preference for Alexa Fluor 405 
when compared to Cascade Blue and fluorescein-methotrexate (Figure 3.11, Figure 3.12, Table 3.2). 
OATP2B1 is an emerging candidate in drug-transporter interaction studies, however, there is no 
available large-scale fluorescence-based scaling method for OATP2B1. This assay might be the new 
approach to screen for OATP2B1-mediated DDIs. 
Our new substrates are excellent candidates for the establishment of a new functional assay, given the 
high quantum yield, water-solubility, minimal membrane permeability and low pH-sensitivity. 
Moreover, they can be used to measure OATP function in a semi-high throughput format. Calculating 
the z-factor revealed that LDV and CB for OATP1B1 and OATP2B1, and ZV, LDG and AF405 for 
all three hepatic OATPs may be applied in larger-scale drug screening studies (Table 3.2). 
Additionally, using CB and AF405 as test substrates, we could detect OATP-drug interactions. First, 
we showed the inhibitory effect on OATP1B3, OATP1B3 and OATP2B1-mediated CB and AF405 
transport with previously identified OATP interacting compounds (Figure 3.14). Furthermore, 
determining the IC50 values for the most used test substrate, estrone-3-sulphate was in good 
agreement with previous measurements (Table 3.3 and kinetics can be seen in Figure 3.15). The value 
of the new fluorescent substrate-based assay was also further demonstrated when our group verified 
OATP2B1-drug interactions and determined IC50 values following a smaller scale (101 compounds) 
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toxicity screen between OATP2B1 and FDA approved drugs in A431 cells expressing OATP2B1 
(Chapter III-Results part II, also Windt el al.206).  
Unfortunately, indirect transport assays cannot reveal the true nature of the interaction (substrate or 
inhibitor) between the tested molecule and OATP, the transport should be confirmed by direct 
transport measurements, such as mass spectrometry or direct labeling. However, the use of in vitro 
cell-based test systems, like our new method is a cheaper way to screen more extensive compound 
libraries in the early stages of drug development. 
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Summary 
In drug development, there is an increasing interest in transporter families, especially the ones with a 
multispecific substrate profile, such as OATPs. Methods to investigate and predict OATP-drug and 
OATP-food interactions are necessary for early drug development.  
In this thesis, we developed new fluorescent methods to investigate the human OATP transport 
function. The investigation evaluated Sf9 cells and several mammalian cell lines as models for in vitro 
transport measurements and tested and identified several fluorescent compounds that can be 
transported by the human OATP family. In the first part of the dissertation, we identified sodium-
fluorescein as a pan-OATP substrate and proved that Sf9 cells are suitable to express functional OATP 
proteins. These two components helped to develop a new fluorescent substrate-based functional assay 
to identify novel OATP-drug interactions. In the second part of the dissertation, we found additional 
fluorescent substrates for OATP1B1, OATP1B3 and OATP2B2: Zombie Violet, Live/Dead Violet, 
Live/Dead Green, Cascade Blue and Alexa Fluor 405. These test substrates are better suited for semi-
high throughput assays compared to sodium-fluorescein and fluorescein-methotrexate.  
We advanced our first system and established a new in vitro assay in mammalian cells that can be used 
in semi-high throughput compound library screens. Moreover, we demonstrated that Live/Dead 
Green can be used for OATP-function based enrichment of OATP1B1, OATP1B3 and OATP2B1 
expression in different cell lines. 
We further emphasized the fact that OATPs' transporter activity is highly influenced by the 
extracellular pH environment. 
In summary, the use of in vitro cell-based test systems that overexpress OATPs may be helpful 
towards to predict human PK of pre- and clinical drugs and assess risk for possible DDIs. Such 
knowledge may clarify differences observed in tissue distribution regarding OATPs and their 
polymorphisms and transporter-drug interactions. Even more, it might help to utilize OATPs for 
targeted drug delivery.  
Further application of the fluorescence-based methods developed during my Ph.D. work: 
The newly developed fluorescence techniques opened new possibilities toward the establishment of 
model systems and methods for the investigation of human OATPs. 
1. Based on the best performing viability dyes, we performed further screening among the 
available viability and other routinely applied fluorescent dyes. This search resulted in the 
identification of novel fluorescent substrates for OATP1A2 and OATP1C1 that allowed the 
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development of novel assays for determining their function and drug interactions (Bakos et 
al., 2019140). 
2. The fluorescence-based sorting method allowed the generation of human (A431 and HEK 
293) cell lines with high expression levels of OATPs that is often a challenge due to the 
unfavorable effect of forced expression of OATPs in cell lines159. The generation of these cell 
lines provided the basis for further screening of fluorescent substrates and the establishment 
of model cell lines appropriate for medium scale drug screenings (Windt et al., 2019206).  
3. With the help of the established fluorescence methods, I contributed to the identification of a 
novel OATP2B1 drug substrate, erlotinib (Bauer et al., 2018173). 
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Összefoglalás 
A gyógyszerfejlesztési ágazatban folyamatosan növekszik az érdeklődés olyan transzporter családok 
iránt, amelyek multispecifikus szubsztrát profillal rendelkeznek. Erre egy kiváló példa az OATP 
fehérjecsalád, hiszen a gyógyszerfejlesztési folyamat során szükség van OATP-gyógyszer és OATP-
étel kölcsönhatások kimutatására alkalmas módszerek kidolgozására. Ez azért fontos, hogy már a 
fejlesztés korai stádiumában ki tudják szűrni, hogy egy esetleges jövőbeli gyógyszer, OATP-kel való 
kölcsönhatás révén okozhat e káros mellékhatásokat.  
A dolgozatban új, általunk kifejlesztett fluoreszcens módszereket mutatunk be, melyek alkalmasak a 
humán OATP-k transzportfunkciójának vizsgálatára. A kifejlesztett in vitro módszerrel Sf9 és emlős 
sejtvonalakban expresszáltatott OATP fehérjéken teszteltünk transzporter funkciót és azonosítottunk 
új fluoreszcens OATP szubsztrátokat.  
A disszertáció első részében bemutatjuk, hogy az Sf9 sejtek alkalmasak funkcionális OATP-k 
termeltetésére, ezen felül bemutatjuk, hogy a nátrium-fluoreszcein egy általános OATP-szubsztrát 
Ezen eredmények hozzájárultak egy új fluoreszcens szubsztrát-alapú funkcionális mérési módszer 
kidolgozásához; mellyel új OATP-gyógyszer kölcsönhatásokat vagyunk képesek azonosítani. 
A disszertáció második részében további fluoreszcens OATP1B1, OATP1B3 és OATP2B1 
szubsztrátokat fedeztünk fel, mint Zombie Violet, Live / Dead Violet, Live / Dead Green, Cascade 
Blue és Alexa Fluor 405. Ezek a teszt szubsztrátok az előzetes mérések során jobbnak bizonyultak 
közepes áteresztőképességű vizsgálatok lebonyolításához, mint a korábban leírt nátrium-fluoreszcein 
és fluoreszcein-metotrexát.  
A korábbi módszerünket tovább fejlesztve, az újonnan felfedezett szubsztrátokat is felhasználva, egy 
in vitro, emlős sejt-alapú, közepes-áteresztőképességű esszét dolgoztunk ki gyógyszer könyvtárak 
tesztelésére. Továbbá bemutatjuk, hogy a Live/Dead Green festék használható OATP-funkció alapú 
sejt szortolásra, amivel növelhető az össz-OATP1B1, OATP1B3 és OATP2B1 fehérje mennyisége 
különböző sejtvonalakban. 
Továbbá hangsúlyozzuk és példákkal szemléltetjük az OATP-k pH-függő transzporter aktivitását.  
Az eredményeinket összefoglalva megállapíthatjuk, hogy egy in vitro, magas OATP-expressziót mutató 
sejt-alapú teszt rendszer alkalmas lehet preklinikai fázisban és már forgalomban lévő gyógyszerek 
farmakokinetikai paramétereinek és lehetséges gyógyszerkölcsönhatások becslésére. Az így 
megszerzett tudás segíthet jobban megérteni az OATP-k és izoformáik között megfigyelt funkcionális 
Page | 88  
 
és szöveti elolszlásbeli különbségeket és transzporter-gyógyszer kölcsönhatásokat. Továbbá, esetleges 
kaput nyit OATP-ken keresztüli célzott gyógyszer bejuttatásra. 
 
További példák a doktori képzésem során kifejlesztett fluoreszcencia-alapú módszerek 
alkalmazhatóságára: 
Az újonnan kifejlesztett fluoreszcens technikák lehetőséget teremtettek újabb modell rendszerek 
kidolgozására, melyekkel a humán OATP család vizsgálata válik lehetővé. 
1. A jól teljesítő viabilitási festékekből kiindulva, további viabilitási és más általánosan elérhető 
fluoreszcens festékeket teszteltünk OATP-expresszáló sejtvonalakban. Ezzel új 
szubsztrátokat, továbbá új módszereket fejlesztett és írt le a csoportunk a kevésbé jellemzett 
OATP1A2 és OATP1C1 fehérjék és gyógyszerkölcsönhatásaik jellemzésére. (Bakos et al., 
2019140). 
2. A fluoreszcencia-alapú szortolási módszer lehetőséget teremtett magas OATP-expressziót 
mutató humán eredetű sejtvonalak (A431 és HEK293) létrehozásához, ami a legtöbb esetben 
már önmagában kihívás, hiszen a túl magas OATP-expressziót és a hozzá köthető funkciót 
rosszul tolerálják egyes sejtvonalak. (Cesar-Razquin et al., 2015159) Az OATP-ket nagy 
mennyiségben termelő sejtvonalak segítségével drog toxicitási vizsgálatokra alkalmas közepes 
áteresztő képességű teszt rendszer hoztunk létre. (Windt et al., 2019206).  
3. Az általunk kifejlesztett fluoreszcens módszerek segítségével, hozzájárultunk egy új OATP2B1 
szubsztrát (Erlotinib) felfedezéséhez és ezen kölcsönhatás jellemzéséhez (Bauer et al., 2018173). 
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